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Guidelines summarize and evaluate all available evidence on a par-
ticular issue at the time of the writing process, with the aim of assist-
ing health professionals in selecting the best management strategies
for an individual patient with a given condition, taking into account
the impact on outcome, as well as the risk–benefit ratio of particu-
lar diagnostic or therapeutic means. Guidelines and recommenda-
tions should help health professionals to make decisions in their
daily practice. However, the final decisions concerning an individual
patient must be made by the responsible health professional(s) in
consultation with the patient and caregiver as appropriate.
A great number of Guidelines have been issued in recent years by
the European Society of Cardiology (ESC) as well as by other soci-
eties and organisations. Because of the impact on clinical practice,
quality criteria for the development of guidelines have been estab-
lished in order to make all decisions transparent to the user. The re-
commendations for formulating and issuing ESC Guidelines can be
found on the ESC website (http://www.escardio.org/Guidelines-
&-Education/Clinical-Practice-Guidelines/Guidelines-development/
Writing-ESC-Guidelines). ESC Guidelines represent the official pos-
ition of the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC to re-
present professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a
comprehensive review of the published evidence for management
(including diagnosis, treatment, prevention and rehabilitation) of
a given condition according to ESC Committee for Practice
Guidelines (CPG) policy. A critical evaluation of diagnostic and
therapeutic procedures was performed, including assessment of
the risk–benefit ratio. Estimates of expected health outcomes for
larger populations were included, where data exist. The level of
evidence and the strength of the recommendation of particular
management options were weighed and graded according to prede-
fined scales, as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels provided declara-
tions of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http://
www.escardio.org/guidelines). Any changes in declarations of inter-
est that arise during the writing period must be notified to the ESC
and updated. The Task Force received its entire financial support
from the ESC without any involvement from the healthcare
industry.
The ESC CPG supervises and coordinates the preparation of new
Guidelines produced by task forces, expert groups or consensus pa-
nels. The Committee is also responsible for the endorsement pro-
cess of these Guidelines. The ESC Guidelines undergo extensive
review by the CPG and external experts. After appropriate revi-
sions the Guidelines are approved by all the experts involved in
the Task Force. The finalized document is approved by the CPG
for publication in the European Heart Journal. The Guidelines
were developed after careful consideration of the scientific and
medical knowledge and the evidence available at the time of
their dating.
The task of developing ESC Guidelines covers not only integra-
tion of the most recent research, but also the creation of education-
al tools and implementation programmes for the recommendations.
To implement the guidelines, condensed pocket guidelines versions,
summary slides, booklets with essential messages, summary cards
for non-specialists, and an electronic version for digital applications
(smartphones, etc.) are produced. These versions are abridged and
thus, if needed, one should always refer to the full text version,
which is freely available on the ESC website. The National Societies
of the ESC are encouraged to endorse, translate and implement all
ESC Guidelines. Implementation programmes are needed because it
Table 1 Classes of recommendations
Classes of 
recommendations
Suggested wording to use
Class I Evidence and/or general 
agreement that a given treatment 





divergence of opinion about the 
Conflicting evidence and/or a
usefulness/efficacy of the given
favour of usefulness/efficacy.
Usefulness/efficacy is less well
treatment or procedure. 
Class IIa Weight of evidence/opinion is in Should be considered
Class IIb
established by evidence/opinion. 
May be considered
Class III Evidence or general agreement 
that the given treatment or 
procedure is not useful/effective,  
and in some cases may be harmful. 
Is not recommended
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has been shown that the outcome of disease may be favourably in-
fluenced by the thorough application of clinical recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines,
disseminating them and implementing them into clinical practice.
Health professionals are encouraged to take the ESC Guidelines
fully into account when exercising their clinical judgment, as well as
in the determination and the implementation of preventive, diagnos-
tic or therapeutic medical strategies. However, the ESC Guidelines
do not override in any way whatsoever the individual responsibility
of health professionals to make appropriate and accurate decisions
in consideration of each patient’s health condition and in consult-
ation with that patient and the patient’s caregiver where appropriate
and/or necessary. It is also the health professional’s responsibility to
verify the rules and regulations applicable to drugs and devices at the
time of prescription.
2. Justification/scope of the
problem
Infective endocarditis (IE) is a deadly disease.1,2 Despite improve-
ments in its management, IE remains associated with high mortality
and severe complications. Until recently, guidelines on IE were
mostly based on expert opinion because of the low incidence of
the disease, the absence of randomized trials and the limited num-
ber of meta-analyses.3– 7
The 2009 ESC Guidelines on the prevention, diagnosis and treat-
ment of IE8 introduced several innovative concepts, including limita-
tion of antibiotic prophylaxis to the highest-risk patients, a focus on
healthcare-associated IE and identification of the optimal timing for
surgery. However, several reasons justify the decision of the ESC to
update the previous guidelines: the publication of new large series of
IE, including the first randomized study regarding surgical therapy;9
important improvements in imaging procedures,10 particularly in the
field of nuclear imaging; and discrepancies between previous guide-
lines.5– 8 In addition, the need for a collaborative approach involving
primary care physicians, cardiologists, surgeons, microbiologists,
infectious disease (ID) specialists and frequently other specialists—
namely the ‘Endocarditis Team’—has been underlined recently11,12
and will be developed in these new guidelines.
The main objective of the current Task Force was to provide clear
and simple recommendations, assisting healthcare providers in their
clinical decision making. These recommendations were obtained by
expert consensus after thorough review of the available literature.
An evidence-based scoring system was used, based on a classifica-
tion of the strength of recommendations and the levels of evidence.
3. Prevention
3.1 Rationale
The principle of antibiotic prophylaxis for IE was developed on the
basis of observational studies and animal models and aimed at pre-
venting the attachment of bacteria onto the endocardium after tran-
sient bacteraemia following invasive procedures. This concept led to
the recommendation for antibiotic prophylaxis in a large number of
patients with predisposing cardiac conditions undergoing a wide
range of procedures.13
The restriction of indications for antibiotic prophylaxis was in-
itiated in 2002 because of changes in pathophysiological concep-
tions and risk–benefit analyses as follows:14
† Low-grade but repeated bacteraemia occurs more frequently dur-
ing daily routine activities such as toothbrushing, flossing or chew-
ing, and even more frequently in patients with poor dental health.15
The accountability of low-grade bacteraemia was demonstrated in
an animal model.16 The risk of IE may therefore be related more to
cumulative low-grade bacteraemia during daily life rather than spor-
adic high-grade bacteraemia after dental procedures.
† Most case–control studies did not report an association between
invasive dental procedures and the occurrence of IE.17– 19
† The estimated risk of IE following dental procedures is very low.
Antibiotic prophylaxis may therefore avoid only a small number
of IE cases, as shown by estimations of 1 case of IE per 150 000
dental procedures with antibiotics and 1 per 46 000 for proce-
dures unprotected by antibiotics.20
† Antibiotic administration carries a small risk of anaphylaxis, which
may become significant in the event of widespread use. However,
the lethal risk of anaphylaxis seems very low when using oral
amoxicillin.21
† Widespread use of antibiotics may result in the emergence of
resistant microorganisms.13
† The efficacy of antibiotic prophylaxis on bacteraemia and the oc-
currence of IE has only been proven in animal models. The effect
on bacteraemia in humans is controversial.15
† No prospective randomized controlled trial has investigated the
efficacy of antibiotic prophylaxis on the occurrence of IE and it is
unlikely that such a trial will be conducted given the number of
subjects needed.22
These points have been progressively taken into account in most
guidelines, including the 2009 ESC guidelines,5,8,23 – 26 and led to
the restriction of antibiotic prophylaxis to the highest-risk patients
(patients with the highest incidence of IE and/or highest risk of
adverse outcome from IE).
In 2008 the National Institute for Health and Care Excellence
(NICE) guidelines went a step further and advised against any anti-
biotic prophylaxis for dental and non-dental procedures whatever
Table 2 Levels of evidence
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 




Consensus of opinion of the experts and/
or small studies, retrospective studies, 
registries.
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the patient’s risk.27 The authors concluded there was an absence of
benefit of antibiotic prophylaxis, which was also highly cost-
ineffective. These conclusions have been challenged since estima-
tions of the risks of IE are based on low levels of evidence due to
multiple extrapolations.28,29
Four epidemiological studies have analysed the incidence of IE fol-
lowing restricted indications for antibiotic prophylaxis. The analysis
of 2000–2010 national hospital discharge codes in the UK did not
show an increase in the incidence of streptococcal IE after the re-
lease of NICE guidelines in 2008.30 The restriction of antibiotic
prophylaxis was seen in a 78% decrease in antibiotic prescriptions
before dental care. However, residual prescriptions raised concerns
regarding a persisting use of antibiotic prophylaxis. A survey
performed in 2012 in the UK showed that the majority of cardiolo-
gists and cardiac surgeons felt that antibiotic prophylaxis was
necessary in patients with valve prosthesis or prior IE.31 Recently
an analysis of UK data collected from 2000 to 2013 showed a signifi-
cant increase in the incidence of IE in both high-risk and lower-risk
patients in the UK starting in 2008.32 However, this temporal relation-
ship should not be interpreted as a direct consequence of the NICE
guidelines. These findings may be influenced by confounding factors,
in particular changes in the number of patients at risk of hospitaliza-
tions and healthcare-associated IE. Moreover, microbiological data
were not available. Thus we cannot know whether that increase is
due to the microbiological species covered by antibiotic prophylaxis.
A repeated prospective 1-year population-based French survey
did not show an increase in the incidence of IE, in particular strepto-
coccal IE, between 1999 and 2008, whereas antibiotic prophylaxis
had been restricted for native valve disease since 2002.33
Two studies from the USA did not find a negative impact of the
abandonment of antibiotic prophylaxis in native valve disease in the
2007 American Heart Association guidelines.34,35 A more recent
analysis on an administrative database found an increase in the inci-
dence of IE hospitalizations between 2000 and 2011, with no signifi-
cant change after the change of American guidelines in 2007.36 The
increase in IE incidence was observed for all types of microorgan-
isms, but was significant for streptococci after 2007.36 It was not sta-
ted whether this was due to oral streptococci and if intermediate-
or high-risk patients were involved.
The present guidelines maintain the principle of antibiotic
prophylaxis in high-risk patients for the following reasons:
† The remaining uncertainties regarding estimations of the risk of
IE, which play an important role in the rationale of NICE
guidelines.
† The worse prognosis of IE in high-risk patients, in particular those
with prosthetic IE.
† The fact that high-risk patients account for a much smaller num-
ber than patients at intermediate risk, thereby reducing potential
harm due to adverse events of antibiotic prophylaxis.
3.2 Population at risk
Patients with the highest risk of IE can be placed in three categories
(Table 3):
(1) Patients with a prosthetic valve or with prosthetic material used
for cardiac valve repair: these patients have a higher risk of IE, a
higher mortality from IE and more often develop complications
of the disease than patients with native valves and an identical
pathogen.37 This also applies to transcatheter-implanted pros-
theses and homografts.
(2) Patients with previous IE: they also have a greater risk of new IE,
higher mortality and higher incidence of complications than pa-
tients with a first episode of IE.38
(3) Patients with untreated cyanotic congenital heart disease
(CHD) and those with CHD who have postoperative palliative
shunts, conduits or other prostheses.39,40 After surgical repair
with no residual defects, the Task Force recommends prophy-
laxis for the first 6 months after the procedure until endothelia-
lisation of the prosthetic material has occurred.
Although American Heart Association/American College of
Cardiology guidelines recommend prophylaxis in cardiac transplant
recipients who develop cardiac valvulopathy, this is not supported
by strong evidence5,25,41 and is not recommended by the ESC
Task Force.
Antibiotic prophylaxis is not recommended for patients at
intermediate risk of IE, i.e. any other form of native valve disease
(including the most commonly identified conditions: bicuspid
aortic valve, mitral valve prolapse and calcific aortic stenosis).
Nevertheless, both intermediate- and high-risk patients should
be advised of the importance of dental and cutaneous hygiene13
(Table 4). These measures of general hygiene apply to patients
and healthcare workers and should ideally be applied to the general
population, as IE frequently occurs without known cardiac disease.
Table 3 Cardiac conditions at highest risk of infective
endocarditis for which prophylaxis should be
considered when a high-risk procedure is performed
Recommendations Classa Levelb
Antibiotic prophylaxis should be considered for
patients at highest risk for IE:
(1) Patients with any prosthetic valve, including a
transcatheter valve, or those in whom any
prosthetic material was used for cardiac valve
repair.
(2) Patients with a previous episode of IE.
(3) Patients with CHD:
(a) Any type of cyanotic CHD.
(b) Any type of CHD repaired with a
prosthetic material, whether placed
surgically or by percutaneous techniques,
up to 6 months after the procedure or
lifelong if residual shunt or valvular
regurgitation remains.
IIa C
Antibiotic prophylaxis is not recommended in
other forms of valvular or CHD.
III C











3.3 Situations and procedures at risk
3.3.1 Dental procedures
At-risk procedures involve manipulation of the gingival or periapical
region of the teeth or perforation of the oral mucosa (including scal-
ing and root canal procedures) (Table 5).15,20 The use of dental im-
plants raises concerns with regard to potential risk due to foreign
material at the interface between the buccal cavity and blood.
Very few data are available.42 The opinion of the Task Force is
that there is no evidence to contraindicate implants in all patients
at risk. The indication should be discussed on a case-by-case basis.
The patient should be informed of the uncertainties and the need
for close follow-up.
3.3.2 Other at-risk procedures
There is no compelling evidence that bacteraemia resulting from re-
spiratory tract procedures, gastrointestinal or genitourinary proce-
dures, including vaginal and caesarean delivery, or dermatological or
musculoskeletal procedures causes IE (Table 5).
3.4 Prophylaxis for dental procedures
Antibiotic prophylaxis should only be considered for patients at
highest risk for endocarditis, as described in Table 3, undergoing at-
risk dental procedures listed in Table 5, and is not recommended in
other situations. The main targets for antibiotic prophylaxis in these
patients are oral streptococci. Table 6 summarizes the main regimens
of antibiotic prophylaxis recommended before dental procedures.
Fluoroquinolones and glycopeptides are not recommended due to
their unclear efficacy and the potential induction of resistance.
Table 5 Recommendations for prophylaxis of
infective endocarditis in the highest-risk patients
according to the type of at-risk procedure
Recommendations Classa Levelb
A. Dental procedures
† Antibiotic prophylaxis should only be
considered for dental procedures requiring
manipulation of the gingival or periapical
region of the teeth or perforation of the oral
mucosa
IIa C
† Antibiotic prophylaxis is not recommended
for local anaesthetic injections in non-infected
tissues, treatment of superficial caries,
removal of sutures, dental X-rays, placement
or adjustment of removable prosthodontic or
orthodontic appliances or braces or following
the shedding of deciduous teeth or trauma to
the lips and oral mucosa
III C
Continued
Table 4 Non-specific prevention measures to be
followed in high-risk and intermediate-risk patients
These measures should ideally be applied to the general
population and particularly reinforced in high-risk patients:
• Strict dental and cutaneous hygiene. Dental follow-up should be 
performed twice a year in high-risk patients and yearly in the others.
• Disinfection of wounds.
• Eradication or decrease of chronic bacterial carriage: skin, urine.
• Curative antibiotics for any focus of bacterial infection.
• No self-medication with antibiotics.
• Strict infection control measures  for any at-risk procedure.
• Discourage piercing and tattooing. 
• Limit the use of infusion catheters and invasive procedure when 
possible. Favour peripheral over central catheters, and systematic 
replacement of the peripheral catheter every 3–4 days. Strict 




B. Respiratory tract proceduresc
† Antibiotic prophylaxis is not recommended
for respiratory tract procedures, including
bronchoscopy or laryngoscopy, or transnasal
or endotracheal intubation
III C
C. Gastrointestinal or urogenital procedures or TOEc
† Antibiotic prophylaxis is not recommended
for gastroscopy, colonoscopy, cystoscopy,
vaginal or caesarean delivery or TOE
III C
D. Skin and soft tissue proceduresc
† Antibiotic prophylaxis is not recommended
for any procedure
III C
TOE ¼ transoesophageal echocardiography.
aClass of recommendation.
bLevel of evidence.
cFor management when infections are present, please refer to Section 3.5.3.
Table 6 Recommended prophylaxis for high-risk
dental procedures in high-risk patients
Situation Antibiotic
Single-dose 30–60 minutes 
before procedure
Adults Children










Clindamycin 600 mg orally 
or i.v.
20 mg/kg orally 
or i.v.
aAlternatively, cephalexin 2 g i.v. for adults or 50 mg/kg i.v. for children, cefazolin or
ceftriaxone 1 g i.v. for adults or 50 mg/kg i.v. for children.
Cephalosporins should not be used in patients with anaphylaxis, angio-oedema, or
urticaria after intake of penicillin or ampicillin due to cross-sensitivity.
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Cephalosporins should not be used in patients with anaphylaxis,
angio-oedema or urticaria after intake of penicillin or ampicillin due
to cross-sensitivity.
3.5 Prophylaxis for non-dental
procedures
Systematic antibiotic prophylaxis is not recommended for non-
dental procedures. Antibiotic therapy is only needed when invasive
procedures are performed in the context of infection.
3.5.1 Respiratory tract procedures
Patients listed in Table 3 who undergo an invasive respiratory tract
procedure to treat an established infection (i.e. drainage of an ab-
scess) should receive an antibiotic regimen that contains an anti-
staphylococcal drug.
3.5.2 Gastrointestinal or genitourinary procedures
In the case of an established infection or if antibiotic therapy is in-
dicated to prevent wound infection or sepsis associated with a
gastrointestinal or genitourinary tract procedure in patients de-
scribed in Table 3, it is reasonable that the antibiotic regimen in-
cludes an agent active against enterococci (i.e. ampicillin,
amoxicillin or vancomycin; only in patients unable to tolerate beta-
lactams). The use of intrauterine devices was regarded as contra-
indicated, but this was based on low levels of evidence. Use of an
intrauterine device is now considered acceptable, in particular
when other contraceptive methods are not possible and in women
at low risk of genital infections.43
3.5.3 Dermatological or musculoskeletal procedures
For patients described in Table 3 undergoing surgical procedures
involving infected skin (including oral abscesses), skin structure or
musculoskeletal tissue, it is reasonable that the therapeutic regimen
contains an agent active against staphylococci and beta-haemolytic
streptococci.
3.5.4 Body piercing and tattooing
These growing societal trends are a cause for concern, particularly
for individuals with CHD who are at increased susceptibility for the
acquisition of IE. Case reports of IE after piercing and tattooing are
increasing, particularly when piercing involves the tongue,44 al-
though publication bias may over- or underestimate the problem.
Currently no data are available on the incidence of IE after such pro-
cedures and the efficacy of antibiotics for prevention. Education of
patients at risk of IE is paramount. They should be informed about
the hazards of piercing and tattooing and these procedures should
be discouraged not only in high-risk patients, but also in those with
native valve disease. If undertaken, procedures should be performed
under strictly sterile conditions, though antibiotic prophylaxis is not
recommended.
3.5.5 Cardiac or vascular interventions
In patients undergoing implantation of a prosthetic valve, any type of
prosthetic graft or pacemakers, perioperative antibiotic prophylaxis
should be considered due to the increased risk and adverse
outcome of an infection45– 49 (Table 7). The most frequent microor-
ganisms underlying early (1 year after surgery) prosthetic valve
infections are coagulase-negative staphylococci (CoNS) and
Staphylococcus aureus. Prophylaxis should be started immediately be-
fore the procedure, repeated if the procedure is prolonged and ter-
minated 48 h afterwards. A randomized trial has shown the efficacy
of 1 g intravenous (i.v.) cefazolin on the prevention of local and sys-
temic infections before pacemaker implantation.45 Preoperative
screening of nasal carriage of S. aureus is recommended before elect-
ive cardiac surgery in order to treat carriers using local mupirocin
and chlorhexidine.46,47 Rapid identification techniques using gene
amplification are useful to avoid delaying urgent surgery. Systematic
local treatment without screening is not recommended. It is strongly
recommended that potential sources of dental sepsis should be
eliminated at least 2 weeks before implantation of a prosthetic valve
or other intracardiac or intravascular foreign material, unless the lat-
ter procedure is urgent.48
3.5.6 Healthcare-associated infective endocarditis
Healthcare-associated IE represents up to 30% of all cases of IE and
is characterized by an increasing incidence and a severe prognosis,
thus presenting an important health problem.50,51 Although routine
antimicrobial prophylaxis administered before most invasive
Table 7 Recommendations for antibiotic
prophylaxis for the prevention of local and systemic
infections before cardiac or vascular interventions
Recommendations Classa Levelb Ref.c
Preoperative screening of nasal carriage of
Staphylococcus aureus is recommended




recommended before placement of a
pacemaker or implantable cardioverter
defibrillator
I B 45
Potential sources of sepsis should be
eliminated ≥2 weeks before implantation
of a prosthetic valve or other intracardiac




should be considered in patients
undergoing surgical or transcatheter
implantation of a prosthetic valve,
intravascular prosthetic or other foreign
material
IIa C
Systematic local treatment without












procedures is not recommended, aseptic measures during the inser-
tion and manipulation of venous catheters and during any invasive
procedures, including in outpatients, are mandatory to reduce the
rate of this healthcare-associated IE.52
In summary, these guidelines propose continuing to limit antibiot-
ic prophylaxis to patients at high risk of IE undergoing the
highest-risk dental procedures. They highlight the importance of
hygiene measures, in particular oral and cutaneous hygiene. Epi-
demiological changes are marked by an increase in IE due to
staphylococcus and of healthcare-associated IE, thereby high-
lighting the importance of non-specific infection control mea-
sures.51,53 This should concern not only high-risk patients, but
should also be part of routine care in all patients since IE occur-
ring in patients without previously known heart disease now ac-
counts for a substantial and increasing incidence. This means
that although antibiotic prophylaxis should be restricted to the
highest-risk patients, preventive measures should be maintained
or extended to all patients with cardiac disease.
Although this section of the guidelines on IE prophylaxis is
based on weak evidence, they have been strengthened recently
by epidemiological surveys, most of which did not show an in-
creased incidence of IE due to oral streptococci.33 – 35 Their ap-
plication by patients should follow a shared decision-making
process. Future challenges are to gain a better understanding
of the mechanisms associated with valve infection, the
adaptation of prophylaxis to the ongoing epidemiological
changes and the performance of specific prospective surveys
on the incidence and characteristics of IE.
4. The ‘Endocarditis Team’
IE is a disease that needs a collaborative approach for the following
reasons:
† First, IE is not a single disease, but rather may present with very
different aspects depending on the first organ involved, the
underlying cardiac disease (if any), the microorganism involved,
the presence or absence of complications and the patient’s char-
acteristics.8 No single practitioner will be able to manage and
treat a patient in whom the main clinical symptoms might be car-
diac, rheumatological, infectious, neurological or other.
† Second, a very high level of expertise is needed from practitioners
from several specialties, including cardiologists, cardiac surgeons,
ID specialists, microbiologists, neurologists, neurosurgeons, ex-
perts in CHD and others. Echocardiography is known to have a
major importance in the diagnosis and management of IE. How-
ever, other imaging techniques, including magnetic resonance im-
aging (MRI), multislice computed tomography (MSCT), and
nuclear imaging, have also been shown to be useful for diagnosis,
follow-up and decision making in patients with IE.10 Including all of
these specialists in the team is becoming increasingly important.
† Finally, about half of the patients with IE undergo surgery during
the hospital course.54 Early discussion with the surgical team is
important and is considered mandatory in all cases of compli-
cated IE [i.e. endocarditis with heart failure (HF), abscess or em-
bolic or neurological complications].
Therefore the presence of an Endocarditis Team is crucial. This
multidisciplinary approach has already been shown to be useful
in the management of valve disease11 (the ‘Heart Valve Clinic’),
particularly in the selection of patients for transcatheter aortic valve
implantation procedures (‘Heart Team’ approach).55 In the field of
IE, the team approach adopted in France, including standardized
medical therapy, surgical indications following guideline recommen-
dations and 1 year of close follow-up, has been shown to significant-
ly reduce the 1-year mortality, from 18.5% to 8.2%.12 Other authors
have recently reported similar results.56 Taking these reports to-
gether, such a team approach has been recommended recently as
class IB in the 2014 American Heart Association/American College
of Cardiology guideline for the management of patients with valvular
heart disease.25
The present Task Force on the management of IE of the ESC
strongly supports the management of patients with IE in refer-
ence centres by a specialized team (the ‘Endocarditis Team’).
The main characteristics of the Endocarditis Team and the
referring indications are summarized in Tables 8 and 9.
Table 8 Characteristics of the ‘Endocarditis Team’
When to refer a patient with IE to an ‘Endocarditis Team’
in a reference centre 
1. Patients with complicated IE (i.e. endocarditis with HF, abscess, or 
embolic or neurological complication or CHD), should be referred 
early and managed in a reference centre with immediate surgical 
facilities.
2. Patients with non-complicated IE can be initially managed in a non-
reference centre, but with regular communication with the reference 
centre, consultations with the multidisciplinary ‘Endocarditis Team’, and, 
when needed, with external visit to the reference centre.
Characteristics of the reference centre
1. Immediate access to diagnostic procedures should be possible, 
including TTE, TOE, multislice CT, MRI, and nuclear imaging.
2. Immediate access to cardiac surgery should be possible during the 
early stage of the disease, particularly in case of complicated IE (HF, 
abscess, large vegetation, neurological, and embolic complications).
3. Several specialists should be present on site (the ‘Endocarditis Team’), 
including at least cardiac surgeons, cardiologists, anaesthesiologists, ID 
specialists, microbiologists and, when available, specialists in valve 
diseases, CHD, pacemaker extraction, echocardiography and other 
cardiac imaging techniques, neurologists, and facilities for
neurosurgery and interventional neuroradiology . 
Role of the ‘Endocarditis Team’
1. The ‘Endocarditis Team’ should have meetings on a regular basis in
order to discuss cases, take surgical decisions, and define the type of
follow-up.
2. The ‘Endocarditis Team’ chooses the type, duration, and mode of 
follow up of antibiotic therapy, according to a standardized protocol, 
following the current guidelines.
3. The ‘Endocarditis Team’ should participate in national or international 
registries, publicly report the mortality and morbidity of their centre, 
and be involved in a quality improvement programme, as well as in a 
patient education programme.
4. The follow-up should be organized on an outpatient visit basis at a 
frequency depending on the patient’s clinical status (ideally at 1, 3, 
6, and 12 months after hospital discharge, since the majority of events 
occur during this period57).
CHD ¼ Congenital heart disease; CT ¼ computed tomography; HF ¼ heart
failure; ID ¼ Infectious disease; IE ¼ infective endocarditis; MRI ¼ magnetic
resonance imaging; TOE ¼ transoesophageal echocardiography; TTE ¼
transthoracic echocardiography.
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The diverse nature and evolving epidemiological profile of IE ensure
that it remains a diagnostic challenge. The clinical history of IE is
highly variable according to the causative microorganism, the pres-
ence or absence of pre-existing cardiac disease, the presence or ab-
sence of prosthetic valves or cardiac devices and the mode of
presentation. Thus IE should be suspected in a variety of very differ-
ent clinical situations. It may present as an acute, rapidly progressive
infection, but also as a subacute or chronic disease with low-grade
fever and non-specific symptoms that may mislead or confuse initial
assessment. Patients may therefore present to a variety of specialists
who may consider a range of alternative diagnoses, including chronic
infection; rheumatological, neurological and autoimmune diseases;
or malignancy. The early involvement of a cardiologist and an ID
specialist to guide management is highly recommended.
Up to 90% of patients present with fever, often associated with sys-
temic symptoms of chills, poor appetite and weight loss. Heart mur-
murs are found in up to 85% of patients. Up to 25% of patients have
embolic complications at the time of diagnosis. Therefore IE has to be
suspected in any patient presenting with fever and embolic phenom-
ena. Classic signs may still be seen in the developing world in subacute
forms of IE, although peripheral stigmata of IE are increasingly uncom-
mon elsewhere, as patients generally present at an early stage of the
disease. However, vascular and immunological phenomena such as
splinter haemorrhages, Roth spots and glomerulonephritis remain
common. Emboli to the brain, lung or spleen occur in 30% of patients
and are often the presenting feature.58 In a febrile patient, diagnostic
suspicion may be strengthened by laboratory signs of infection, such
as elevated C-reactive protein (CRP) or erythrocyte sedimentation
rate (ESR), leucocytosis, anaemia and microscopic haematuria.
However, these signs lack specificity and have not been integrated
into current diagnostic criteria. Atypical presentation is common in
elderly or immunocompromised patients,59 in whom fever is less
common than in younger individuals. A high index of suspicion and
low threshold for investigation are therefore essential in these and
other high-risk groups, such as those with CHD or prosthetic valves,
to exclude IE or avoid delays in diagnosis.
5.2 Laboratory findings
In addition to specialized microbiological and imaging investigations,
a number of laboratory investigations and biomarkers have been
evaluated in sepsis/sepsis syndromes and endocarditis. The large
number of proposed potential biomarkers reflects the complex
pathophysiology of the disease process, involving pro- and anti-
inflammatory processes, humoral and cellular reactions and both
circulatory and end-organ abnormalities.60 However, owing to their
poor positive predictive value for the diagnosis of sepsis and lack of
specificity for endocarditis, these biomarkers have been excluded
from being major diagnostic criteria and are only used to facilitate
risk stratification.
Sepsis severity may be indicated by the demonstration of a number
of laboratory investigations, including the degree of leucocytosis/leu-
copoenia, the number of immature white cell forms, concentrations
of CRP and procalcitonin, ESR and markers of end-organ dysfunction
(lactataemia, elevated bilirubin, thrombocytopaenia and changes in
serum creatinine concentration); however, none are diagnostic for
IE.61 Further, certain laboratory investigations are used in surgical
scoring systems relevant to risk stratification in patients with IE, in-
cluding bilirubin, creatinine and platelet count [Sequential Organ Fail-
ure Assessment (SOFA) score] and creatinine clearance [European
System for Cardiac Operative Risk Evaluation (EuroSCORE) II]. Final-
ly, the pattern of increase in inflammatory mediators or immune
complexes may support, but not prove, the diagnosis of IE, including
the finding of hypocomplementaemia in the presence of elevated
antineutrophil cytoplasmic antibody in endocarditis-associated vas-
culitis or, where lead infection is suspected clinically, the laboratory
finding of a normal procalcitonin and white cell count in the presence
of significantly elevated CRP and/or ESR.62
5.3 Imaging techniques
Imaging, particularly echocardiography, plays a key role in both the
diagnosis and management of IE. Echocardiography is also useful
for the prognostic assessment of patients with IE, for its follow-up
under therapy and during and after surgery.63 Echocardiography is
particularly useful for initial assessment of the embolic risk and in
decision making in IE. Transoesophageal echocardiography (TOE)
plays a major role both before and during surgery (intraoperative
echocardiography). However, the evaluation of patients with IE
is no longer limited to conventional echocardiography, but
should include several other imaging techniques such as MSCT,
MRI, 18F-fluorodeoxyglucose (FDG) positron emission tomography
(PET)/computed tomography (CT) or other functional imaging
modalities.10
5.3.1 Echocardiography
Echocardiography, either transthoracic echocardiography (TTE) or
TOE, is the technique of choice for the diagnosis of IE, and plays a
Table 9 Recommendations for referring patients to
the reference centre
Recommendations Classa Levelb Ref.c
Patients with complicated IE should be
evaluated and managed at an early stage in
a reference centre, with immediate
surgical facilities and the presence of a
multidisciplinary ‘Endocarditis Team’,
including an ID specialist, a microbiologist,
a cardiologist, imaging specialists, a cardiac
surgeon and, if needed, a specialist in CHD
IIa B 12,56
For patients with uncomplicated IE
managed in a non-reference centre, early
and regular communication with the
reference centre and, when needed, visits
to the reference centre should be made
IIa B 12,56












key role in the management and monitoring of these patients.64,65
Echocardiography must be performed as soon as IE is suspected.
TOE must be performed in case of negative TTE when there is a
high index of suspicion for IE, particularly when TTE is of suboptimal
quality. TOE should also be performed in patients with positive TTE
to rule out local complications. The indications of echocardiograph-
ic examination for diagnosis and follow-up of patients with sus-
pected IE are summarized in Table 10 and Figure 1. In patients
with S. aureus bacteraemia, echocardiography is justified in view of
the frequency of IE in this setting, the virulence of this organism
and its devastating effects once intracardiac infection is estab-
lished.66,67 In these patients, TTE or TOE should be considered ac-
cording to individual patient risk factors and the mode of acquisition
of S. aureus bacteraemia.66,67
Table 10 Role of echocardiography in infective
endocarditis
Recommendations Classa Levelb Ref.c
A. Diagnosis
† TTE is recommended as the
first-line imaging modality in
suspected IE.
I B 64,65
† TOE is recommended in all
patients with clinical suspicion





† TOE is recommended in patients
with clinical suspicion of IE,
when a prosthetic heart
valve or an intracardiac device is
present.
I B 64,71
† Repeat TTE and /or TOE within
5–7 days is recommended in case
of initially negative examination
when clinical suspicion of IE
remains high.
I C




† TOE should be considered in
patients with suspected IE, even
in cases with positive TTE,
except in isolated right-sided
native valve IE with good




B. Follow-up under medical therapy
† Repeat TTE and/or TOE are
recommended as soon as a
new complication of IE is
suspected (new murmur,





Recommendations Classa Levelb Ref.c
† Repeat TTE and/or TOE should be
considered during follow-up of
uncomplicated IE, in order to detect
new silent complications and
monitor vegetation size. The timing
and mode (TTE or TOE) of repeat
examination depend on the initial
findings, type of microorganism, and
initial response to therapy.
IIa B 64,72
C. Intraoperative echocardiography
† Intraoperative echocardiography is
recommended in all cases of IE
requiring surgery.
I B 64,73
D. Following completion of therapy
† TTE is recommended at completion
of antibiotic therapy for evaluation
of cardiac and valve morphology and
function.
I C
HF ¼ heart failure; IE ¼ infective endocarditis; TOE ¼ transoesophageal








If initial TOE is negative but high suspicion for IE remains, 











IE = infective endocarditis; TOE = transoesophageal echocardiography; TTE = transthoracic 
echocardiography. 
aTOE is not mandatory in isolated right-sided native valve IE with good quality TTE examination and 
unequivocal echocardiographic  
Figure 1 Indications for echocardiography in suspected infect-
ive endocarditis.
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Three echocardiographic findings are major criteria in the diag-
nosis of IE: vegetation, abscess or pseudoaneurysm and new dehis-
cence of a prosthetic valve8,64,65 (see Table 11 for anatomical and
echocardiographic definitions). Nowadays, the sensitivity for the
diagnosis of vegetations in native and prosthetic valves is 70%
and 50%, respectively, for TTE and 96% and 92%, respectively,
for TOE.64,65 Specificity has been reported to be around 90%
for both TTE and TOE. Identification of vegetations may be diffi-
cult in the presence of pre-existing valvular lesions (mitral valve
prolapse, degenerative calcified lesions), prosthetic valves, small
vegetations (, 2 – 3 mm), recent embolization and in non-
vegetant IE. Diagnosis may be particularly challenging in IE affecting
intracardiac devices, even with the use of TOE.
False diagnosis of IE may occur, and in some instances it may be
difficult to differentiate vegetations from thrombi, Lambl’s excres-
cences, cusp prolapse, chordal rupture, valve fibroelastoma, de-
generative or myxomatous valve disease, strands, systemic lupus
(Libman – Sacks) lesions, primary antiphospholipid syndrome,
rheumatoid lesions or marantic vegetations.74 Therefore the re-
sults of the echocardiographic study must be interpreted with cau-
tion, taking into account the patient’s clinical presentation and the
likelihood of IE.
The sensitivity of TTE for the diagnosis of abscesses is about 50%,
compared with 90% for TOE. Specificity higher than 90% has been
reported for both TTE and TOE.64,65 Small abscesses may be diffi-
cult to identify, particularly in the earliest stage of the disease, in the
postoperative period and in the presence of a prosthetic valve. IE
must always be suspected in patients with new periprosthetic regur-
gitation, even in the absence of other echocardiographic findings
of IE.64
In cases with an initially negative examination, repeat TTE/TOE
must be performed 5–7 days later if the clinical level of suspicion
is still high, or even earlier in the case of S. aureus infection.75 Other
imaging techniques should also be used in this situation (see section
5.5). Finally, follow-up echocardiography to monitor complications
and response to treatment is mandatory (Figure 1).
Real-time three-dimensional (3D) TOE allows the analysis of 3D
volumes of cardiac structures in any possible plane. A recent study
has shown that conventional TOE underestimates vegetation size
and that 3D TOE is a feasible technique for the analysis of vegetation
morphology and size that may overcome the shortcomings of con-
ventional TOE, leading to a better prediction of the embolic risk in
IE.76 3D TOE is particularly useful in the assessment of perivalvular
extension of the infection, prosthetic valve dehiscence and valve
perforation.77 Although in clinical practice 3D TOE is increasingly
performed along with conventional TOE in many centres, at present
3D TOE should still be regarded as a supplement to standard echo-
cardiography in most cases.
5.3.2 Multislice computed tomography
The potential risks of vegetation embolization and/or haemo-
dynamic decompensation during coronary angiography (when in-
dicated) have led to proposals to consider MSCT coronary
angiography as an alternative technique for some patients with
endocarditis.78
MSCT can be used to detect abscesses/pseudoaneurysms with a
diagnostic accuracy similar to TOE, and is possibly superior in the
provision of information regarding the extent and consequences of
any perivalvular extension, including the anatomy of pseudoaneur-
ysms, abscesses and fistulae.79 In aortic IE, CT may additionally be
useful to define the size, anatomy and calcification of the aortic
valve, root and ascending aorta, which may be used to inform sur-
gical planning. In pulmonary/right-sided endocarditis, CT may re-
veal concomitant pulmonary disease, including abscesses and
infarcts.
In the evaluation of prosthetic valve dysfunction, one recent
study has suggested that MSCT may be equivalent or superior
to echocardiography for the demonstration of prostheses-related
vegetations, abscesses, pseudoaneurysms and dehiscence.80 How-
ever, large comparative studies between the two techniques
are missing, and echocardiography should always be performed
first.
The higher sensitivity of MRI compared with CT for the detection
of cerebral lesions is well known and has been confirmed in the con-
text of endocarditis. However, in the critically ill patient, CT may be
more feasible and practical and is an acceptable alternative when
MRI is not available. MSCT angiography allows complete
Table 11 Anatomical and echocardiographic
definitions
Surgery/necropsy Echocardiography
Vegetation Infected mass attached to 
an endocardial structure 




mass on valve or other 
endocardial structures, 
or on implanted 
intracardiac material. 
Abscess Perivalvular cavity 
with necrosis and 
purulent material not 





with echodense or 
echolucent appearance.
Pseudoaneurysm Perivalvular cavity 
communicating with the 
cardiovascular lumen.
Pulsatile perivalvular 
echo-free space, with 
colour-Doppler
detected.












cavities through a 
perforation.
Valve aneurysm Saccular outpouching of 
valvular tissue. 
Saccular bulging of 
valvular tissue. 
Dehiscence of a 
prosthetic valve




by TTE/TOE, with or 
without rocking motion 
of the prosthesis.
TOE ¼ transoesophageal echocardiography; TTE ¼ transthoracic
echocardiography.
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visualization of the intracranial vascular tree and carries a lower con-
trast burden and risk of permanent neurological damage than con-
ventional digital subtraction angiography, with a sensitivity of 90%
and specificity of 86%.81 Where subarachnoid and/or intraparench-
ymal haemorrhage is detected, other vascular imaging (i.e. angiog-
raphy) is required to diagnose or exclude a mycotic aneurysm if
not detected on CT.
Contrast-enhanced MSCT has a high sensitivity and specificity
for the diagnosis of splenic and other abscesses; however, the differ-
entiation with infarction can be challenging. MSCT angiography pro-
vides a rapid and comprehensive exploration of the systemic arterial
bed. Detailed multiplanar and 3D contrast-enhanced angiographic
reconstructions allow vascular mapping with identification and char-
acterization of peripheral vascular complications of IE and their
follow-up.82
5.3.3 Magnetic resonance imaging
Given its higher sensitivity than CT, MRI increases the likelihood of
detecting cerebral consequences of IE. Different studies including
systematic cerebral MRI during acute IE have consistently reported
frequent lesions, in 60–80% of patients.83 Regardless of neurological
symptoms, most abnormalities are ischaemic lesions (in 50–80% of
patients), with more frequent small ischaemic lesions than larger
territorial infarcts.84 Other lesions are found in ,10% of patients
and are parenchymal or subarachnoidal haemorrhages, abscesses
or mycotic aneurysms.83– 86
Systematic cerebral MRI has an impact on the diagnosis of IE
since it adds one minor Duke criterion87 in patients who have
cerebral lesions and no neurological symptoms. In one study, find-
ings of cerebral MRI upgraded the diagnosis of IE in 25% of patients
presenting initially with non-definite IE, thereby leading to earlier
diagnosis.85
Cerebral microbleeds are detected only when using gradient
echo T2* sequences and are found in 50–60% of patients.85 Micro-
bleeds represent small areas of haemosiderin deposits and are
considered as an indicator of small vessel disease. The lack of
concordance between ischaemic lesions and microbleeds and the
differences in their predictive factors suggest that microbleeds are
not of embolic origin.86,88 Therefore, although IE and the presence
of microbleeds are strongly linked, microbleeds should not be
considered as a minor criterion in the Duke classification.87
Cerebral MRI is, in the majority of cases, abnormal in IE patients
with neurological symptoms.89 It has a higher sensitivity than CT in
the diagnosis of the culprit lesion, in particular with regards to
stroke, transient ischaemic attack and encephalopathy. MRI may
also detect additional cerebral lesions that are not related to clinical
symptoms. Cerebral MRI has no impact on the diagnosis of IE in pa-
tients with neurological symptoms, as they already have one minor
Duke criterion, but MRI may impact the therapeutic strategy, par-
ticularly the timing of surgery.89 In patients without neurological
symptoms, MRI shows cerebral lesions in at least half of the patients,
most often ischaemic lesions.90 Systematic abdominal MRI detects
lesions in one of three patients evaluated, most often affecting the
spleen.91 Ischaemic lesions are most common, followed by ab-
scesses and haemorrhagic lesions. Abdominal MRI findings have
no incremental impact on the diagnosis of IE when taking into ac-
count the findings of cerebral MRI.
To summarize, cerebral MRI allows for a better lesion character-
ization in patients with IE and neurological symptoms, whereas its
impact on IE diagnosis is marked in patients with non-definite IE
and without neurological symptoms.
5.3.4 Nuclear imaging
With the introduction of hybrid equipment for both conventional
nuclear medicine [e.g. single-photon emission CT (SPECT)/CT]
and PET (i.e. PET/CT), nuclear molecular techniques are evolving
as an important supplementary method for patients with sus-
pected IE and diagnostic difficulties. SPECT/CT imaging relies on
the use of autologous radiolabelled leucocytes (111In-oxine or
99mTc-hexamethylpropyleneamine oxime) that accumulate in a
time-dependent fashion in late images versus earlier images,92
whereas PET/CT is generally performed using a single acquisition
time point (generally at 1 h) after administration of 18F-FDG, which
is actively incorporated in vivo by activated leucocytes, monocyte-
macrophages and CD4+ T-lymphocytes accumulating at the sites
of infection.
Several reports have shown promising results for radiolabelled
white blood cell (WBC) SPECT/CT and 18F-FDG PET/CT imaging
in IE. The main added value of using these techniques is the reduc-
tion in the rate of misdiagnosed IE, classified in the ‘Possible IE’ cat-
egory using the Duke criteria, and the detection of peripheral
embolic and metastatic infectious events.93 Limitations to the use
of 18F-FDG PET/CT are represented by localization of septic emboli
in the brain, due to the high physiological uptake of this tracer in the
brain cortex, and to the fact that at this site, metastatic infections are
generally ,5 mm, the spatial resolution threshold of current PET/
CT scanners.
Caution must be exercised when interpreting 18F-FDG PET/CT
results in patients who have recently undergone cardiac surgery,
as a postoperative inflammatory response may result in non-specific
18F-FDG uptake in the immediate postoperative period. Further-
more, a number of pathological conditions can mimic the pattern
of focally increased 18F-FDG uptake that is typically observed in
IE, such as active thrombi, soft atherosclerotic plaques, vasculitis,
primary cardiac tumours, cardiac metastasis from a non-cardiac tu-
mour, post-surgical inflammation and foreign body reactions.94
Radiolabelled WBC SPECT/CT is more specific for the detection
of IE and infectious foci than 18F-FDG PET/CT and should be pre-
ferred in all situations that require enhanced specificity.95 Disadvan-
tages of scintigraphy with radiolabelled WBC are the requirement
of blood handling for radiopharmaceutical preparation, the duration
of the procedure, which is more time consuming than PET/CT, and a
slightly lower spatial resolution and photon detection efficiency
compared with PET/CT.
An additional promising role of 18F-FDG PET/CT may be seen in
patients with established IE, in whom it could be employed to moni-
tor response to antimicrobial treatment. However, sufficient data
are not available at this time to make a general recommendation.
5.4 Microbiological diagnosis
5.4.1 Blood culture–positive infective endocarditis
Positive blood cultures remain the cornerstone of diagnosis and pro-
vide live bacteria for both identification and susceptibility testing. At
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least three sets are taken at 30-min intervals, each containing 10 mL of
blood, and should be incubated in both aerobic and anaerobic atmo-
spheres. Sampling should be obtained from a peripheral vein rather
than from a central venous catheter (because of the risk of contam-
ination and misleading interpretation), using a meticulous sterile tech-
nique. This is virtually always sufficient to identify the usual causative
microorganisms. The need for culture before antibiotic administra-
tion is self-evident. In IE, bacteraemia is almost constant and has
two implications: (i) there is no rationale for delaying blood sampling
with peaks of fever and (ii) virtually all blood cultures are positive. As a
result, a single positive blood culture should be regarded cautiously
for establishing the diagnosis of IE. The microbiology laboratory
should be aware of the clinical suspicion of IE at the time of blood cul-
ture sampling. When a microorganism has been identified, blood cul-
tures should be repeated after 48–72 h to check the effectiveness of
treatment. Automated machines perform continuous monitoring of
bacterial growth, which ensures quick provision of reports to physi-
cians. When a positive blood culture bottle is identified, presumptive
identification is based on Gram staining. This information is immedi-
ately given to clinicians in order to adapt presumptive antibiotic ther-
apy. Complete identification is routinely achieved within 2 days, but
may require longer for fastidious or atypical organisms. Since the de-
lay between blood culture sampling and definitive identification of the
organism responsible for the bacteraemia and antibiotic susceptibility
testing is long, many improvements have been proposed to speed up
the process of detection and identification. One of the most recent
procedures for rapid bacterial identification is based on peptide spec-
tra obtained by matrix-assisted laser desorption ionization
time-of-flight mass spectrometry. This technique has recently de-
monstrated its usefulness in clinical microbiology; it also has the po-
tential for direct identification of bacterial colonies in the blood
culture bottle supernatant.96
5.4.2 Blood culture–negative infective endocarditis
Blood culture–negative IE (BCNIE) refers to IE in which no causa-
tive microorganism can be grown using the usual blood culture
methods. BCNIE can occur in up to 31% of all cases of IE and often
poses considerable diagnostic and therapeutic dilemmas. BCNIE
most commonly arises as a consequence of previous antibiotic
administration, underlying the need for withdrawing antibiotics
and repeating blood cultures in this situation. BCNIE can be caused
by fungi or fastidious bacteria, notably obligatory intracellular bac-
teria. Isolation of these microorganisms requires culturing them on
specialized media, and their growth is relatively slow. According to
local epidemiology, systematic serological testing for Coxiella bur-
netii, Bartonella spp., Aspergillus spp., Mycoplasma pneumonia, Brucel-
la spp. and Legionella pneumophila should be proposed, followed by
specific polymerase chain reaction (PCR) assays for Tropheryma
whipplei, Bartonella spp. and fungi (Candida spp., Aspergillus spp.)
from the blood97 (Table 12). Most studies using blood PCR
for the diagnosis of BCNIE have highlighted the importance of
Streptococcus gallolyticus and Streptococcus mitis, enterococci,
S. aureus, Escherichia coli and fastidious bacteria, the respective
prevalence of which varies according to the status and condition
of the patient.98
When all microbiological assays are negative, the diagnosis of
non-infectious endocarditis should systematically be considered
and assays for antinuclear antibodies as well as antiphospholipid syn-
drome {anticardiolipin antibodies [immunoglobulin (Ig)G] and
anti-b2-glycoprotein 1 antibodies [IgG and IgM]} should be per-
formed. When all other tests are negative and the patient has a por-
cine bioprosthesis together with markers of allergic response,
anti-pork antibodies should be sought.99
5.4.3 Histological diagnosis of infective endocarditis
Pathological examination of resected valvular tissue or embolic frag-
ments remains the gold standard for the diagnosis of IE. All tissue
samples that are excised during the course of the surgical removal
of cardiac valves must be collected in a sterile container without
fixative or culture medium. The entire sample should be taken to
the diagnostic microbiology laboratory for optimal recovery and
identification of microorganisms.
5.4.4 Proposed strategy for a microbiological diagnostic
algorithm in suspected IE
A proposed diagnostic scheme is provided in Figure 2. When there is
clinical suspicion of IE and blood cultures remain negative at 48 h,
liaison with the microbiologist is necessary. A suggested strategy is
the use of a diagnostic kit including blood cultures and systematic
serological testing for C. burnetii, Bartonella spp., Aspergillus spp.,
L. pneumophila, Brucella spp., M. pneumonia, as well as rheumatoid
factor, the serological tests for antiphospholipid syndrome [anticar-
diolipin (IgG) and anti-b2-glycoprotein 1 (IgG and IgM)], antinuclear
antibodies and anti-pork antibodies. In addition, cardiac valvular ma-
terials obtained at surgery have to be subjected to systematic cul-
ture, histological examination and PCR aimed at documenting the
presence of fastidious organisms.
Table 12 Investigation of rare causes of blood culture
negative infective endocarditis
Pathogen Diagnostic procedures
Brucella spp. Blood cultures, serology, culture, immunohistology, 
and PCR of surgical material.
Coxiella burnetii Serology (IgG phase l >1:800), tissue culture, 
immunohistology, and PCR of surgical material.
Bartonella spp. Blood cultures, serology, culture, immunohistology, 
and PCR of surgical material.
Tropheryma 
whipplei
Histology and PCR of surgical material.
Mycoplasma spp. Serology, culture, immunohistology, and PCR of 
surgical material.
Legionella spp. Blood cultures, serology, culture, immunohistology, 
and PCR of surgical material.
Fungi Blood cultures, serology, PCR of surgical material.
Ig ¼ immunoglobulin; PCR ¼ polymerase chain reaction.
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Besides the pathological aspect obtained after valve surgery, in clinical
practice the diagnosis of IE usually relies on the association between
an infective syndrome and recent endocardial involvement. This is the
cornerstone of the various criteria proposed to facilitate the difficult
diagnosis of this disease. Thus, in 2000, the modified Duke criteria
were recommended for diagnostic classification (Table 13). These cri-
teria are based on clinical, echocardiographic and biological findings, as
well as the results of blood cultures and serologies.87 This classifica-
tion has a sensitivity of approximately 80% overall when the criteria
are evaluated at the end of patient follow-up in epidemiological stud-
ies.100 However, the modified Duke criteria show a lower diagnostic
accuracy for early diagnosis in clinical practice, especially in the case of
prosthetic valve endocarditis (PVE) and pacemaker or defibrillator
lead IE, for which echocardiography is normal or inconclusive in up
to 30% of cases.101,102 Recent advances in imaging techniques have re-
sulted in an improvement in identification of endocardial involvements
and extracardiac complications of IE.10,103 Thus recent works have de-
monstrated that cardiac/whole-body CT scan, cerebral MRI, 18F-FDG
PET/CT and radiolabelled leucocyte SPECT/CT might improve the
detection of silent vascular phenomena (embolic events or infectious
aneurysms) as well as endocardial lesions.79,80,83–85,93,94,104–108 The
addition of the results of these imaging modalities may improve the
sensitivity of the modified Duke criteria in difficult cases.
BCNIE = blood culture-negative infective endocarditis; IE = infective endocarditis; PCR = polymerase chain reaction.
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Figure 2 Microbiological diagnostic algorithm in culture-positive and culture-negative IE.
Table 13 Definition of infective endocarditis
according to the modified Duke criteria (adapted from
Li et al.87)
Pathological criteria
• Microorganisms demonstrated by culture or on histological 
 examination of a vegetation, a vegetation that has embolized, or an 
 intracardiac abscess specimen; or
•  Pathological lesions;  vegetation or intracardiac abscess by 
 histological examination showing active endocarditis
Clinical criteria
• 2 major criteria; or
• 1 major criterion and 3 minor criteria; or
• 5 minor criteria
Possible IE
• 1 major criterion and 1 minor criterion; or
• 3 minor criteria
Rejected IE
• Firm alternate diagnosis; or
• Resolution of symptoms suggesting IE with antibiotic therapy for 
 ≤4 days; or
• No pathological evidence of IE at surgery or autopsy, with antibiotic 
 therapy for ≤4 days; or
• Does not meet criteria for possible IE, as above
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Given the recent published data, the Task Force proposes the
addition of three further points in the diagnostic criteria (Table 14):
(1) The identification of paravalvular lesions by cardiac CT should
be considered a major criterion.
(2) In the setting of the suspicion of endocarditis on a prosthetic
valve, abnormal activity around the site of implantation de-
tected by 18F-FDG PET/CT (only if the prosthesis was im-
planted for .3 months) or radiolabelled leucocyte SPECT/
CT should be considered a major criterion.
(3) The identification of recent embolic events or infectious aneur-
ysms by imaging only (silent events) should be considered a min-
or criterion.
Figure 3 presents the proposed ESC diagnostic algorithm including
the ESC 2015 modified diagnostic criteria. The diagnosis of IE is still
based on the Duke criteria, with a major role of echocardiography
and blood cultures. When the diagnosis remains only ‘possible’ or
even ‘rejected’ but with a persisting high level of clinical suspicion,
echocardiography and blood culture should be repeated and other
imaging techniques should be used, either for diagnosis of cardiac
involvement (cardiac CT, 18F-FDG PET/CT or radiolabelled leuco-
cyte SPECT/CT) or for imaging embolic events (cerebral MRI,
whole-body CT and/or PET/CT). The results of these new investi-
gations should then be integrated in the ESC 2015 modified diagnos-
tic criteria.
Finally, 18F-FDG PET/CT and radiolabelled leucocyte SPECT/CT
have proven their role in the diagnosis of cardiovascular electronic
implanted devices,108 but the data are not sufficient for them to be
included in the diagnostic criteria of the specific topic of IE on pace-
maker or defibrillator leads.
In summary, echocardiography (TTE and TOE), positive blood cul-
tures and clinical features remain the cornerstone of IE diagnosis.
When blood cultures are negative, further microbiological studies
are needed. The sensitivity of the Duke criteria can be improved
by new imaging modalities (MRI, CT, PET/CT) that allow the diag-
nosis of embolic events and cardiac involvement when TTE/TOE
findings are negative or doubtful. These criteria are useful, but
they do not replace the clinical judgement of the Endocarditis Team.
6. Prognostic assessment at
admission
The in-hospital mortality rate of patients with IE varies from 15% to
30%.109 –114 Rapid identification of patients at highest risk of death
Table 14 Definitions of the terms used in the
European Society of Cardiology 2015 modified criteria
for the diagnosis of infective endocarditis
Major criteria
1. Blood cultures positive for IE
a. Typical microorganisms consistent with IE from 2 separate blood 
 cultures: 
 • Viridans streptococci, Streptococcus gallolyticus (Streptococcus 
  bovis), HACEK group, Staphylococcus aureus; or 
 • Community-acquired enterococci, in the absence of a primary 
  focus; or
b. Microorganisms consistent with IE from persistently positive blood 
 cultures: 
 • ≥2 positive blood cultures of blood samples drawn >12 h apart; or 
 • All of 3 or a majority of ≥4 separate cultures of blood (with  
  and last samples drawn ≥1 h apart); or
c. Single positive blood culture for Coxiella burnetii or phase I IgG 
 antibody titre >1:800
2. Imaging positive for IE
a. Echocardiogram positive for IE: 
 • Vegetation; 
 •Abscess, pseudoaneurysm, intracardiac 
 • Valvular perforation or aneurysm; 
 • New partial dehiscence of prosthetic valve.
b. Abnormal activity around the site of prosthetic valve implantation 
 detected by 18F-FDG PET/CT (only if the prosthesis was implanted 
 for >3 months) or radiolabelled leukocytes SPECT/CT. 
 paravalvular lesions by cardiac CT.
Minor criteria
1. Predisposition such as predisposing heart condition, or injection 
 drug use.
2. Fever  as temperature >38°C.
3. Vascular phenomena (including those detected by imaging only): 
 major arterial emboli, septic pulmonary infarcts, infectious (mycotic) 
 aneurysm, intracranial haemorrhage, conjunctival haemorrhages, and 
 Janeway’s lesions.
4. Immunological phenomena: glomerulonephritis, Osler’s nodes, Roth’s 
 spots, and rheumatoid factor.
5. Microbiological evidence: positive blood culture but does not meet 
 a major criterion as noted above or serological evidence of active 
 infection with organism consistent with IE.
CT ¼ computed tomography; FDG ¼ fluorodeoxyglucose; HACEK ¼
Haemophilus parainfluenzae, H. aphrophilus, H. paraphrophilus, H. influenzae,
Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella
corrodens, Kingella kingae, and K. denitrificans; IE ¼ infective endocarditis; Ig ¼
immunoglobulin; PET ¼ positron emission tomography; SPECT ¼ single photon
emission computerized tomography. Adapted from Li et al.87
Clinical suspicion of IE
Modified Duke criteria (Li)
ESC 2015 modified diagnostic criteriab





1 - Repeat echo
    (TTE + TOE)/microbiology
2 - Imaging for embolic eventsa
3 - Cardiac CT
1 - Repeat echo (TTE + TOE)/microbiology
2 - 18 F-FDG PET/CT or Leucocytes labeled SPECT/CT
3 - Cardiac CT
4 - Imaging for embolic eventsa
Rejected IE
Low suspicion
Definite IE Possible  IE Rejected IE
CT = computed tomography; FDG =  IE = infective endocarditis; 
PET = positron emission tomography; SPECT = single photon emission computerized tomography; 
TOE = transoesophageal echocardiography; TTE = transthoracic echocardiography.
aMay include cerebral MRI, whole body CT, and/or PET/CT.              
bSee Table 14. 
Figure 3 European Society of Cardiology 2015 algorithm for
diagnosis of infective endocarditis.
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may offer the opportunity to change the course of the disease (i.e.
emergency or urgent surgery) and improve prognosis.115 Prognosis
in IE is influenced by four main factors: patient characteristics, the
presence or absence of cardiac and non-cardiac complications,
the infecting organism and the echocardiographic findings (Table 15).
The risk of patients with left-sided IE has been formally assessed ac-
cording to these variables.116,117 Patients with HF, periannular com-
plications and/or S. aureus infection are at highest risk of death and
need for surgery in the active phase of the disease.117 When three of
these factors are present, the risk reaches 79%.117 Therefore these
patients with complicated IE should be referred early and managed
in a reference centre with surgical facilities and preferably by an
Endocarditis Team.118 A high degree of co-morbidity, diabetes, sep-
tic shock, moderate-to-severe ischaemic stroke, brain haemorrhage
or the need for haemodialysis are also predictors of poor in-hospital
outcome.111 – 115,119 – 122 Persistence of positive blood cultures
48–72 h after initiation of antibiotic treatment indicates a lack of in-
fection control and is an independent risk factor for in-hospital
mortality.123
Nowadays, 40–50% of patients undergo cardiac surgery during
hospitalization.37,109 – 114 Surgical mortality in IE strongly depends
on its indication. Among patients who need emergency or urgent
surgery, septic shock, persistent signs of infection and renal failure
are predictors of mortality.112,120,124 Predictably, patients with an in-
dication for surgery who cannot proceed due to prohibitive surgical
risk have the worst prognosis.125
In summary, prognostic assessment at admission can be performed
using simple clinical, microbiological and echocardiographic para-
meters and should be used to select the best initial approach. Pa-
tients with persistently positive blood cultures 48–72 h after




Successful treatment of IE relies on microbial eradication by anti-
microbial drugs. Surgery contributes by removing infected material
and draining abscesses. Host defences are of little help. This explains
why bactericidal regimens are more effective than bacteriostatic
therapy, both in animal experiments and in humans.126,127 Amino-
glycosides synergize with cell-wall inhibitors (i.e. beta-lactams and
glycopeptides) for bactericidal activity and are useful for shortening
the duration of therapy (e.g. oral streptococci) and eradicating prob-
lematic organisms (e.g. Enterococcus spp.).
One major hindrance to drug-induced killing is bacterial antibiotic
tolerance. Tolerant microbes are not resistant (i.e. they are still sus-
ceptible to growth inhibition by the drug) but escape drug-induced
killing and may resume growth after treatment discontinuation.
Slow-growing and dormant microbes display phenotypic tolerance
towards most antimicrobials (except rifampin to some extent).
They are present in vegetations and biofilms (e.g. in PVE) and justify
the need for prolonged therapy (6 weeks) to fully sterilize infected
heart valves. Some bacteria carry mutations rendering them tolerant
during both active growth and stationary (dormant) phases. Bacteri-
cidal drug combinations are preferred to monotherapy against tol-
erant organisms.
Drug treatment of PVE should last longer (at least 6 weeks) than
that of native valve endocarditis (NVE) (2–6 weeks), but is other-
wise similar, except for staphylococcal PVE, where the regimen
should include rifampin whenever the strain is susceptible.
In NVE needing valve replacement by a prosthesis during antibiot-
ic therapy, the postoperative antibiotic regimen should be that re-
commended for NVE, not for PVE. In both NVE and PVE, the
duration of treatment is based on the first day of effective antibiotic
therapy (negative blood culture in the case of initial positive blood
culture), not on the day of surgery. A new full course of treatment
should only start if valve cultures are positive, with the choice of
antibiotic being based on the susceptibility of the latest recovered
bacterial isolate.
Finally, there are six important considerations in the current
recommendations:
(1) The indications and pattern of use of aminoglycosides have
changed. They are no longer recommended in staphylococcal
NVE because their clinical benefits have not been demon-
strated, but they can increase renal toxicity;128 when they are
indicated in other conditions, aminoglycosides should be given
in a single daily dose to reduce nephrotoxicity.129




• Prosthetic valve IE
• Diabetes mellitus
• Comorbidity (e.g., frailty, immunosuppression, renal or pulmonary 
 disease)
Clinical complications of IE 
• Heart failure
• Renal failure






• Non-HACEK Gram-negative bacilli
• Periannular complications
• Severe left-sided valve regurgitation
• Low left ventricular ejection fraction
• Pulmonary hypertension
• Large vegetations 
• Severe prosthetic valve dysfunction
• Premature mitral valve closure and other signs of elevated diastolic 
 pressures
HACEK ¼ Haemophilus parainfluenzae, H. aphrophilus, H. paraphrophilus,
H. influenzae, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis,
Eikenella corrodens, Kingella kingae, and K. denitrificans; IE ¼ infective
endocarditis.
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(2) Rifampin should be used only in foreign body infections such as
PVE after 3–5 days of effective antibiotic therapy, once the
bacteraemia has been cleared. The rationale supporting this
recommendation is based on the likely antagonistic effect of
the antibiotic combinations with rifampin against planktonic/
replicating bacteria,130 the synergy seen against dormant bac-
teria within the biofilms and prevention of rifampin-resistant
variants.131
(3) Daptomycin and fosfomycin have been recommended for
treating staphylococcal endocarditis and netilmicin for treat-
ing penicillin-susceptible oral and digestive streptococci, but
they are considered alternative therapies in these guidelines
because they are not available in all European countries.
When daptomycin is indicated, it must be given at high doses
(≥10 mg/kg once daily132) and combined with a second anti-
biotic to increase activity and avoid the development of
resistance.133,134
(4) Only published antibiotic efficacy data from clinical trials and
cohort studies in patients with endocarditis (or bacteraemia if
there are no endocarditis data) have been considered in these
guidelines. Data from experimental endocarditis models have
not been taken into account in most cases.
(5) We are still using the Clinical and Laboratory Standards Institute
minimum inhibitory concentration (MIC) breakpoints instead of
the European Committee on Antimicrobial Susceptibility Test-
ing ones because most endocarditis data are derived from stud-
ies using the former breakpoints.
(6) Although a consensus was obtained for the majority of antibiot-
ic treatments, the optimal treatment of staphylococcal IE and
the empirical treatment are still debated.
7.2 Penicillin-susceptible oral
streptococci and Streptococcus bovis group
Recommended regimens against susceptible streptococci (penicil-
lin MIC ≤0.125 mg/L) are summarized in Table 16.6,8,135,136 The
cure rate is expected to be .95%. In uncomplicated cases, short-
term 2-week therapy can be administered by combining penicillin
or ceftriaxone with gentamicin or netilmicin.137,138 Gentamicin
and netilmicin can be given once daily in patients with IE due to
susceptible streptococci and normal renal function. Ceftriaxone
alone or combined with gentamicin or netilmicin given once a
day is particularly convenient for outpatient therapy.137 – 139 If
desensitization cannot be performed, patients allergic to beta-
lactam should receive vancomycin. Teicoplanin has been proposed
as an alternative,8 but requires loading doses (6 mg/kg/12 h for
3 days) followed by 6–10 mg/kg/day. Loading is critical because
the drug is highly bound (≥98%) to serum proteins and penetrates
slowly into vegetations.140 However, only limited retrospective
studies have assessed its efficacy in streptococcal141 and entero-
coccal142 IE.
7.3 Penicillin-resistant oral streptococci
and Streptococcus bovis group
Penicillin-resistant oral streptococci are classified as inter-
mediate resistant (MIC 0.25 – 2 mg/L) and fully resistant
(MIC ≥4 mg/L). However, some guidelines consider an MIC
.0.5 mg/L as fully resistant.6,8,135 Such resistant streptococci are in-
creasing in number. Large strain collections have reported .30% of
intermediate- and fully resistant Streptococcus mitis and Streptococcus
oralis.142,143 Conversely, .99% of digestive streptococci remain
penicillin susceptible.
Treatment guidelines for penicillin-resistant streptococcal
IE rely on retrospectives series. Compiling four of them, 47 of
60 patients (78%) were treated with penicillin or ceftriaxone,
mostly combined with aminoglycosides, and some with either
clindamycin or aminoglycosides alone.144 – 147 Most penicillin
MICs were ≥1 mg/L. Fifty patients (83%) were cured and 10
(17%) died. Death was not related to resistance, but to the pa-
tients’ underlying conditions.146 Treatment outcomes were
similar in PVE and NVE.145 Hence antibiotic therapy for
penicillin-resistant and penicillin-susceptible oral streptococci is
qualitatively similar (Table 16). However, in penicillin-resistant cases,
aminoglycoside treatment must be given for at least 2 weeks and
short-term therapy regimens are not recommended. Little ex-
perience exists with highly resistant isolates (MIC ≥4 mg/L), but
vancomycin might be preferred in such circumstances (combined




(groups A, B, C, and G)
IE due to S. pneumoniae has become rare since the introduction
of antibiotics. It is associated with meningitis in up to 30% of
cases,149 which requires special consideration in cases with
penicillin resistance. Treatment of penicillin-susceptible strains
(MIC ≤0.06 mg/L) is similar to that of oral streptococci (Table 16),
except for the use of short-term 2-week therapy, which has not
been formally investigated. The same holds true for penicillin inter-
mediate (MIC 0.125–2 mg/L) or resistant strains (MIC ≥4 mg/L)
without meningitis, although for resistant strains some authors
recommend high doses of cephalosporins (e.g. cefotaxime or ceftri-
axone) or vancomycin. In cases with meningitis, penicillin must be
avoided because of its poor penetration of the cerebrospinal fluid,
and should be replaced with ceftriaxone or cefotaxime alone or in as-
sociation with vancomycin150 according to the antibiotic susceptibility
pattern.
IE due to group A, B, C, or G streptococci—including Streptococ-
cus anginosus group (S. constellatus, S. anginosus, and S. intermedius)—
is relatively rare.151 Group A streptococci are uniformly susceptible
to beta-lactams (MIC ≤0.12 mg/L), whereas other serogroups
may display some degree of resistance. IE due to group B strepto-
cocci was once associated with the peripartum period, but it now
occurs in other adults, especially the elderly. Group B, C, and G
streptococci and S. anginosus produce abscesses and thus may re-
quire adjunctive surgery.151 Mortality from group B PVE is very
high and cardiac surgery is recommended.152 Antibiotic treatment
is similar to that of oral streptococci (Table 16), except that short-
term therapy is not recommended. Gentamicin should be given for
2 weeks.
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Table 16 Antibiotic treatment of infective endocarditis due to oral streptococci and Streptococcus bovis groupa
Antibiotic Dosage and route Duration
(weeks)
Classb Levelc Ref.d Comments
Strains penicillin-susceptible (MIC ≤ 0.125 mg/L) oral and digestive streptococci






12–18 million U/day i.v. either in 4–6 doses or continuously
100–200 mg/kg/day i.v. in 4–6 doses
2 g/day i.v. or i.m. in 1 dose
4 I B 6,8,
135–
139
Preferred in patients. 65 years








Penicillin G 200,000 U/kg/day i.v. in 4–6 divided doses
Amoxicillin 300 mg/kg/day i.v. in 4–6 equally divided doses
Ceftriaxone 100 mg/kg/day i.v. or i.m. in 1 dose










12–18 million U/day i.v. either in 4–6 doses or continuously
100–200 mg/kg/day i.v. in 4–6 doses
2 g/day i.v. or i.m. in 1 dose
3 mg/kg/day i.v. or i.m. in 1 dose
4–5 mg/kg/day i.v. in 1 dose




Only recommended in patients
with non-complicated NVE with
normal renal function.







Penicillin G, amoxicillin, and ceftriaxone as above
Gentamicin 3 mg/kg/day i.v. or i.m. in 1 dose or 3 equally divided
doses
In beta-lactam allergic patientsi
Vancomycinj 30 mg/kg/day i.v. in 2 doses 4 I C 6-week therapy recommended
for patients with PVE
Paediatric doses:g
Vancomycin 40 mg/kg/day i.v. in 2 or 3 equally divided doses









24 million U/day i.v. either in 4–6 doses or continuously
200 mg/kg/day i.v. in 4–6 doses
2 g/day i.v. or i.m. in 1 dose
3 mg/kg/day i.v. or i.m. in 1 dose












30 mg/kg/day i.v. in 2 doses
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric doses:g
As above
4 I C 6-week therapy recommended
for patients with PVE
2 I C
Cmin ¼ minimum concentration; IE ¼ infective endocarditis; i.m. ¼ intramuscular; i.v. ¼ intravenous; MIC ¼ minimum inhibitory concentration; NVE ¼ native valve
endocarditis; PVE ¼ prosthetic valve endocarditis; U ¼ units.
aRefer to text for other streptococcal species; bClass of recommendation; cLevel of evidence; dReference(s) supporting recommendations; eOr ampicillin, same dosages as
amoxicillin; fPreferred for outpatient therapy; gPaediatric doses should not exceed adult doses; hRenal function and serum gentamicin concentrations should be monitored once a
week. When given in a single daily dose, pre-dose (trough) concentrations should be , 1 mg/L and post-dose (peak; 1 hours after injection) serum concentrations should be
10–12 mg/L.148; iPenicillin desensitization can be attempted in stable patients; jSerum vancomycin concentrations should achieve 10–15 mg/L at pre-dose (trough) level,
although some experts recommend to increase the dose of vancomycin to 45–60 mg/kg/day i.v. in 2 or 3 divided doses to reach serum trough vancomycin levels (Cmin) of 15–
20 mg/L as in staphylococcal endocarditis. However, vancomycin dose should not exceed 2 g/d unless serum levels are monitored and can be adjusted to obtain a peak plasma
concentration of 30–45 mg/mL 1 hour after completion of the i.v. infusion of the antibiotic; kPatients with penicillin-resistant strains (MIC . 2 mg/L) should be treated as
enterococcal endocarditis (see Table 18).
ESC Guidelines 3093






7.5 Granulicatella and Abiotrophia
(formerly nutritionally variant
streptococci)
Granulicatella and Abiotrophia produce IE with a protracted course,
which is associated with large vegetations (.10 mm), higher rates
of complications and valve replacement (around 50%),153,154
possibly due to delayed diagnosis and treatment. Antibiotic recom-
mendations include penicillin G, ceftriaxone or vancomycin for
6 weeks, combined with an aminoglycoside for at least the first
2 weeks.153,154
7.6 Staphylococcus aureus and
coagulase-negative staphylococci
Staphylococcus aureus is usually responsible for acute and destructive
IE, whereas CoNS produce more protracted valve infections
(except S. lugdunensis155 and some cases of S. capitis).156,157 Table 17
summarizes treatment recommendations for methicillin-susceptible
and methicillin-resistant S. aureus and CoNS in both native and pros-
thetic valve IE. Of note, the addition of an aminoglycoside in
staphylococcal native valve IE is no longer recommended because
it increases renal toxicity.128,158 Short-term (2-week) and oral treat-
ments have been proposed for uncomplicated right-sided native
valve methicillin-susceptible S. aureus (MSSA) IE (see also section
12.4.2), but these regimens cannot be applied to left-sided IE. For
penicillin-allergic patients with MSSA IE, penicillin desensitization
can be attempted in stable patients since vancomycin is inferior to
beta-lactams159 and should not be given. If beta-lactams cannot be
given, where available, daptomycin should be chosen and given in
combination with another effective antistaphylococcal drug to
increase activity and avoid the development of resistance. Some
experts have recommended a combination of high doses of
cotrimoxazole plus clindamycin as an alternative for S. aureus
IE.160 S. lugdunensis is always methicillin susceptible and can be trea-
ted with cloxacillin.155
Staphylococcus aureus PVE carries a very high risk of mortality
(.45%)161 and often requires early valve replacement. Other dif-
ferences in comparison with NVE include the overall duration of
therapy, the use of aminoglycosides and the addition of rifampin
after 3–5 days of effective antibiotic therapy once the bacteraemia
has been cleared. The rationale supporting this recommendation is
based on the antagonistic effect of the antibiotic combinations with
rifampin against planktonic/replicating bacteria and the synergy
seen against dormant bacteria within the biofilm, as it has been
demonstrated in foreign body infection models and clinically in
prosthetic orthopaedic and vascular infections. Although the le-
vel of evidence is poor, adding rifampin to the treatment of
staphylococcal PVE is standard practice, although treatment




Methicillin-resistant S. aureus (MRSA) produces low-affinity penicil-
lin binding protein 2a (PBP2a), which confers cross-resistance to
most beta-lactams. MRSA are usually resistant to multiple
antibiotics, leaving only vancomycin and daptomycin to treat severe
infections. However, vancomycin-intermediate S. aureus (MIC 4–
8 mg/L) and hetero-vancomycin-intermediate S. aureus (MIC
≤2 mg/L, but with subpopulations growing at higher concentra-
tions) have emerged worldwide and are associated with IE treat-
ment failures.165,166 Moreover, some highly vancomycin-resistant
S. aureus strains have been isolated from infected patients in recent
years, requiring new approaches to treatment. In addition, a system-
atic review and meta-analysis of studies published between 1996 and
2011 in patients with MRSA bacteraemia with vancomycin-
susceptible strains (MIC ≤2 mg/L)167 showed that a high vancomy-
cin MIC (≥1.5 mg/L) was associated with higher mortality.
Daptomycin is a lipopeptide antibiotic approved for S. aureus
bacteraemia and right-sided IE.168 Cohort studies of S. aureus
and CoNS IE132,168 – 170 have shown that daptomycin is at least
as effective as vancomycin, and in two cohort studies of MRSA
bacteraemia with high vancomycin MICs (.1 mg/L),171,172 dapto-
mycin was associated with better outcomes (including survival)
compared with vancomycin. Importantly, daptomycin needs to
be administered in appropriate doses and combined with other
antibiotics to avoid further resistance in patients with IE.168,173
For this reason, daptomycin should be given at high doses
(≥10 mg/kg), and most experts recommend it be combined with
beta-lactams133 or fosfomycin134 [beta-lactams (and probably fos-
fomycin) increase membrane daptomycin binding by decreasing
the positive surface charge] for NVE and with gentamicin and ri-
fampin for PVE.168,173,174
Other alternatives include fosfomycin plus imipenem,175 newer
beta-lactams with relatively good PBP2a affinity such as ceftaroline,176
quinupristin–dalfopristin with or without beta-lactams,177,178 beta-
lactams plus oxazolidinones (linezolid),179 beta-lactams plus vanco-
mycin180 and high doses of trimethoprim/sulfamethoxazole and
clindamycin.160 Such cases warrant collaborative management with
an ID specialist.
7.8 Enterococcus spp.
Enterococcal IE is primarily caused by Enterococcus faecalis (90% of
cases) and, more rarely, by Enterococcus faecium (5% of cases) or
other species.181 They pose two major problems. First, entero-
cocci are highly resistant to antibiotic-induced killing, and eradica-
tion requires prolonged administration (up to 6 weeks) of
synergistic bactericidal combinations of two cell wall inhibitors
(ampicillin plus ceftriaxone, which synergize by inhibiting comple-
mentary PBPs) or one cell wall inhibitor with aminoglycosides
(Table 18). Second, they may be resistant to multiple drugs, includ-
ing aminoglycosides [high-level aminoglycoside resistance
(HLAR)], beta-lactams (via PBP5 modification and sometimes
beta-lactamases) and vancomycin.182
Fully penicillin-susceptible strains (penicillin MIC ≤8 mg/L) are
treated with penicillin G or ampicillin (or amoxicillin) combined
with gentamicin. Ampicillin (or amoxicillin) might be preferred since
MICs are two to four times lower. Gentamicin resistance is frequent
in both E. faecalis and E. faecium.182 An aminoglycoside MIC
.500 mg/L (HLAR) is associated with the loss of bactericidal syner-
gism with cell wall inhibitors, and aminoglycosides should not be
used in such conditions. Streptomycin may remain active in such
cases and is a useful alternative.
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Table 17 Antibiotic treatment of infective endocarditis due to Staphylococcus spp.
Antibiotic Dosage and route Duration
(weeks)
Classi Levelj Ref.k Comments
Native valves
Methicillin-susceptible staphylococci







Gentamicin addition is not recommended because clinical










Sulfamethoxazole 4800 mg/day and
Trimethoprim 960 mg/day (i.v. in 4–6 doses)
1800mg/day i.v. in 3 doses





Sulfamethoxazole 60 mg/kg/day and
Trimethoprim 12 mg/kg/day (i.v. in 2 doses)
Clindamycin 40 mg/kg/day (i.v. in 3 doses)
Penicillin-allergic patientsh or methicillin-resistant staphylococci





Cephalosporins (cefazolin 6 g/day or cefotaxime 6 g/day
i.v. in 3 doses) are recommended for penicillin-allergic
patients with non-anaphylactic reactions with
methicillin-susceptible endocarditis
Daptomycin is superior to vancomycin for MSSA and
MRSA bacteraemia with vancomycin MIC . 1 mg/L
*for Stahylococcus aureus
Paediatric doses:g
40 mg/kg/day i.v. in 2–3 equally divided doses
Alternative therapy**:
Daptomycinc,d 10 mg/kg/day i.v. once daily 4–6 IIa C
Paediatric doses:g





Sulfamethoxazole 4800 mg/day and
Trimethoprim 960 mg/day (i.v. in 4–6 doses)
1800mg/day IV in 3 doses














12 g/day i.v. in 4–6 doses
900–1200 mg i.v. or orally in 2 or 3 divided
doses
3 mg/kg/day i.v. or i.m. in 1 or 2 doses
≥ 6 I B 6,8,
135,
136
Starting rifampin 3–5 days later than vancomycin and
gentamicin has been suggested by some experts.
Gentamicin can be given in a single daily dose in order to
reduce renal toxicity
≥ 6 I B
2 I B
Paediatric doses:g
Oxacillin and (flu)cloxacillin as above
Rifampin 20 mg/kg/day i.v. or orally in 3
equally divided doses






30–60 mg/kg/day i.v. in 2–3 doses
900–1200 mg i.v. or orally in 2 or 3 divided
doses
3 mg/kg/day i.v. or i.m. in 1 or 2 doses
Paediatric dosing:g
As above
≥ 6 I B 6,8,
135,
136
Cephalosporins (cefazolin 6 g/day or cefotaxime 6 g/day
i.v. in 3 doses) are recommended for penicillin-allergic
patients with non-anaphylactic reactions with
methicillin-susceptible endocarditis.
Starting rifampin 3–5 days later than vancomycin and
gentamicin has been suggested by some experts.
Gentamicin can be given in a single daily dose in order to
reduce renal toxicity
≥ 6 I B
2 I B
AUC ¼ area under the curve; Cmin ¼ minimum concentration; IE ¼ infective endocarditis; MIC ¼ minimum inhibitory concentration; MRSA ¼ methicillin-resistant
Staphylococcus aureus; MSSA ¼ methicillin-susceptible S. aureus; PVE ¼ prosthetic valve endocarditis.
aRenal function, serum Cotrimoxazole concentrations should be monitored once/week (twice/week in patients with renal failure); bSerum trough vancomycin levels (Cmin)
should be ≥20 mg/L. A vancomycin AUC/MIC .400 is recommended for MRSA infections; cMonitor plasma CPK levels at least once a week. Some experts recommend adding
cloxacillin (2 g/4 h i.v.) or fosfomycin (2 g/6 h i.v.) to daptomycin in order to increase activity and avoid the development of daptomycin resistance; dDaptomycin and fosfomycin
are not available in some European countries; eRifampin is believed to play a special role in prosthetic device infection because it helps eradicate bacteria attached to foreign
material.157 The sole use of rifampin is associated with a high frequency of microbial resistance and is not recommended. Rifampin increases the hepatic metabolism of warfarin
and other drugs; fRenal function and serum gentamicin concentrations should be monitored once/week (twice/week in patients with renal failure); gPaediatric doses should not
exceed adult doses; hPenicillin desensitization can be attempted in stable patients; iClass of recommendation; jLevel of evidence; kReference(s) supporting recommendations.
** No clinical benefit of adding rifampicin or gentamicin
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There have been two important advances in recent years. First is
the demonstration, in several cohort studies of E. faecalis IE including
hundreds of cases, that ampicillin plus ceftriaxone is as effective as
ampicillin plus gentamicin for non-HLAR E. faecalis IE. It is also safer,
without any nephrotoxicity.183 – 185 In addition, this is the combin-
ation of choice for treating HLAR E. faecalis IE. Second, the total dai-
ly dose of gentamicin can be given in a single daily dose instead of the
two or three divided doses recommended up to now, and the length
of the treatment for non-HLAR E. faecalis IE may be safely shortened
from 4–6 weeks to 2 weeks, reducing the rates of nephrotoxicity to
very low levels.129,186,187
Beta-lactam and vancomycin resistance are mainly observed in
E. faecium. Since dual resistance is rare, beta-lactam might be used
against vancomycin-resistant strains and vice versa. Varying results
have been reported with quinupristin–dalfopristin (not active
against E. faecalis), linezolid, daptomycin (combined with ampicillin,
ertapenem or ceftaroline) and tigecycline. Again, these situations
require the expertise of an ID specialist.
7.9 Gram-negative bacteria
7.9.1 HACEK-related species
HACEK Gram-negative bacilli are fastidious organisms and the la-
boratory should be made aware that infection with these agents is
under consideration, as specialist investigations may be required
(see also section 5). Because they grow slowly, standard MIC tests
may be difficult to interpret. Some HACEK-group bacilli produce
beta-lactamases, and ampicillin is therefore no longer the first-line
option. Conversely, they are susceptible to ceftriaxone, other
third-generation cephalosporins and quinolones; the standard
treatment is ceftriaxone 2 g/day for 4 weeks in NVE and for 6
Table 18 Antibiotic treatment of infective endocarditis due to Enterococcus spp.
Antibiotic Dosage and route Duration,
weeks
Classg Levelh Ref.i Comments




200 mg/kg/day i.v. in 4–6 doses







6-week therapy recommended for patients with .3
months symptoms or PVE
2–6** I B
Paediatric doses:e
Ampicillin 300 mg/kg/day i.v. in 4–6
equally divided doses Gentamicin 3 mg/kg/




200 mg/kg/day i.v. in 4–6 doses
4 g/day i.v. or i.m. in 2 doses
6 I B 183–
185
This combination is active against Enterococcus faecalis
strains with and without HLAR, being the
combination of choice in patients with HLAR
E. faecalis endocarditis.
This combination is not active against E. faecium
6 I B
Paediatric doses:e
Amoxicillin as above Ceftriaxone 100 mg/




30 mg/kg/day i.v. in 2 doses
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric doses:e
Vancomycin 40 mg/kg/day i.v. in 2–3




HLAR: high-level aminoglycoside resistance; IE: infective endocarditis; MIC: minimum inhibitory concentration; PBP: penicillin binding protein; PVE: prosthetic valve endocarditis.
aHigh-level resistance to gentamicin (MIC .500 mg/L): if susceptible to streptomycin, replace gentamicin with streptomycin 15 mg/kg/day in two equally divided doses.
bBeta-lactam resistance: (i) if due to beta-lactamase production, replace ampicillin with ampicillin–sulbactam or amoxicillin with amoxicillin–clavulanate; (ii) if due to PBP5
alteration, use vancomycin-based regimens.
cMultiresistance to aminoglycosides, beta-lactams and vancomycin: suggested alternatives are (i) daptomycin 10 mg/kg/day plus ampicillin 200 mg/kg/day i.v. in four to six doses;
(ii) linezolid 2 × 600 mg/day i.v. or orally for ≥8 weeks (IIa, C) (monitor haematological toxicity); (iii) quinupristin–dalfopristin 3 × 7.5 mg/kg/day for ≥8 weeks. Quinupristin–
dalfopristin is not active against E. faecalis; (iv) for other combinations (daptomycin plus ertapenem or ceftaroline), consult infectious diseases specialists.
dMonitor serum levels of aminoglycosides and renal function as indicated in Table 16.
ePaediatric doses should not exceed adult doses.




*Or ampicillin, same dosages as amoxicillin.
**Some experts recommend giving gentamicin for only 2 weeks (IIa, B).
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weeks in PVE. If they do not produce beta-lactamase, ampicillin
(12 g/day i.v. in four or six doses) plus gentamicin (3 mg/kg/day di-
vided into two or three doses) for 4–6 weeks is an option. Cipro-
floxacin (400 mg/8–12 h i.v. or 750 mg/12 h orally) is a less
well-validated alternative.188,189
7.9.2 Non-HACEK species
The International Collaboration on Endocarditis (ICE) reported
non-HACEK Gram-negative bacteria in 49 of 2761 (1.8%) IE
cases.190 Recommended treatment is early surgery plus long-term
(at least 6 weeks) therapy with bactericidal combinations of beta-
lactams and aminoglycosides, sometimes with additional quino-
lones or cotrimoxazole. In vitro bactericidal tests and monitoring
of serum antibiotic concentrations may be helpful. Because of their
rarity and severity, these conditions should be discussed by the
Endocarditis Team or with an ID specialist.
7.10 Blood culture–negative infective
endocarditis
The main causes of BCNIE are summarized in section 5.4.2.191,192
Treatment options are summarized in Table 19.192,193 Con-
sultation with an ID specialist from the Endocarditis Team is
recommended.
7.11 Fungi
Fungi are most frequently observed in PVE and in IE affecting i.v. drug
abusers (IVDAs) and immunocompromised patients.198 Candida and
Aspergillus spp. predominate, the latter resulting in BCNIE.199,200
Mortality is very high (.50%), and treatment necessitates combined
antifungal administration and surgical valve replacement.135,198 – 200
Antifungal therapy for Candida IE includes liposomal amphotericin
B (or other lipid formulations) with or without flucytosine or an
echinocandin at high doses; and for Aspergillus IE, voriconazole is
the drug of choice and some experts recommend the addition of
an echinocandin or amphotericin B.135,198,200,201 Suppressive long-
term treatment with oral azoles (fluconazole for Candida and
voriconazole for Aspergillus) is recommended, sometimes for
life.135,198,201 Consultation with an ID specialist from the Endocardi-
tis Team is recommended.
7.12 Empirical therapy
Treatment of IE should be started promptly. Three sets of blood cul-
tures should be drawn at 30-min intervals before initiation of anti-
biotics.202 The initial choice of empirical treatment depends on
several considerations:
(1) Whether the patient has received previous antibiotic therapy.
(2) Whether the infection affects a native valve or a prosthesis
[and if so, when surgery was performed (early vs. late PVE)].
(3) The place of the infection (community, nosocomial, or non-
nosocomial healthcare-associated IE) and knowledge of the lo-
cal epidemiology, especially for antibiotic resistance and specific
genuine culture-negative pathogens (Table 19).
(4) Cloxacillin/cefazolin administration is associated with
lower mortality rates than other beta-lactams, including
Table 19 Antibiotic treatment of blood culture-negative infective endocarditis (adapted from Brouqui et al.193)
Pathogens Proposed therapya Treatment outcome
Brucella spp. Doxycycline (200 mg/24 h)
plus cotrimoxazole (960 mg/12 h) 
plus rifampin (300–600/24 h) 
for ≥3–6 monthsb orally
Treatment success  as an antibody titre <1:60.
Some authors recommend adding gentamicin for the 
 3 weeks.
C. burnetii
(agent of Q fever)
Doxycycline (200 mg/24 h) 
plus hydroxychloroquine (200–600 mg/24 h)c orally
(>18 months of treatment)
Treatment success  as anti-phase I IgG titre
<1:200, and IgA and IgM titres <1:50.
Bartonella spp.d Doxycycline 100 mg/12 h orally for 4 weeks 
plus gentamicin (3 mg/24 h) i.v. for 2 weeks 
Treatment success expected in ≥90%.
Legionella spp.  (500 mg/12 h) i.v. or orally for ≥6 weeks
or clarithromycin (500 mg/12 h) i.v. for 2 weeks, then
orally for 4 weeks 
plus rifampin (300–1200 mg/24 h)
Optimal treatment unknown.
Mycoplasma spp.  (500 mg/12 h) i.v. or orally for ≥6 monthse Optimal treatment unknown.
T. whipplei 
(agent of Whipple’s disease)f
Doxycycline (200 mg/24 h) 
plus hydroxychloroquine (200–600 mg/24 h)c orally for 
≥18 months
Long-term treatment, optimal duration unknown.
ID ¼ infectious disease; IE ¼ infective endocarditis; Ig ¼ immunoglobulin; i.v. ¼ intravenous; U ¼ units.
aOwing to the lack of large series, the optimal duration of treatment of IE due to these pathogens is unknown. The presented durations are based on selected case reports.
Consultation with an ID specialist is recommended.
bAddition of streptomycin (15 mg/kg/24 h in 2 doses) for the first few weeks is optional.
cDoxycycline plus hydroxychloroquine (with monitoring of serum hydroxychloroquine levels) is significantly superior to doxycycline.194
dSeveral therapeutic regimens have been reported, including aminopenicillins (ampicillin or amoxicillin, 12 g/24 h i.v.) or cephalosporins (ceftriaxone, 2 g/24 h i.v.) combined with
aminoglycosides (gentamicin or netilmicin).195 Dosages are as for streptococcal and enterococcal IE (Tables 16 and 18).196,197
eNewer fluoroquinolones (levofloxacin, moxifloxacin) are more potent than ciprofloxacin against intracellular pathogens such as Mycoplasma spp., Legionella spp., and Chlamydia spp.
fTreatment of Whipple’s IE remains highly empirical. In the case of central nervous system involvement, sulfadiazine 1.5 g/6 h orally must be added to doxycycline. An alternative
therapy is ceftriaxone (2 g/24 h i.v.) for 2–4 weeks or penicillin G (2 million U/4 h) and streptomycin (1 g/24 h) i.v. for 2–4 weeks followed by cotrimoxazole (800 mg/12 h) orally.
Trimethoprim is not active against T. whipplei. Successes have been reported with long-term therapy (.1 year).
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amoxicillin/clavulanic acid or ampicillin/sulbactam,203 and
vancomycin for empirically treating MSSA bacteraemia/
endocarditis.159
Suggested regimens for empirical treatment in acute patients
are summarized in Table 20. NVE and late PVE regimens should
cover staphylococci, streptococci and enterococci. Early PVE or
healthcare-associated IE regimens should cover methicillin-resistant
staphylococci, enterococci and, ideally, non-HACEK Gram-negative
pathogens. Once the pathogen is identified (usually in ,48 h), the
antibiotic treatment must be adapted to its antimicrobial susceptibil-
ity pattern.
7.13 Outpatient parenteral antibiotic
therapy for infective endocarditis
Outpatient parenteral antibiotic therapy (OPAT) is used to consoli-
date antimicrobial therapy once critical infection-related complica-
tions are under control (e.g. perivalvular abscesses, acute HF, septic
emboli and stroke).204 – 207 Two different phases may be identified
during the course of antibiotic therapy: (i) a first critical phase
(the first 2 weeks of therapy), during which OPAT has a restricted
indication; and (ii) a second, continuation phase (beyond 2 weeks of
therapy), where OPAT may be feasible. Table 21 summarizes the
salient questions to address when considering OPAT for IE.205
Table 20 Proposed antibiotic regimens for initial empirical treatment of infective endocarditis in acute severely ill
patients (before pathogen identification)a
Antibiotic Dosage and route Classb Levelc Comments







12 g/day i.v. in 4–6 doses
12 g/day i.v. in 4–6 doses
3 mg/kg/day i.v. or i.m. in 1
dose
IIa C




30–60 mg/kg/day i.v. in 2–3
doses










30 mg/kg/day i.v. in 2 doses
3 mg/kg/day i.v. or i.m. in 1
dose
900–1200 mg i.v. or orally
in 2 or 3 divided doses
IIb C
Rifampin is only recommended for PVE and it should be started 3–5 days later than
vancomycin and gentamicin has been suggested by some experts. In healthcare
associated native valve endocarditis, some experts recommend in settings with a
prevalence of MRSA infections .5% the combination of cloxacillin plus
vancomycin until they have the final S. aureus identification
BCNIE ¼ blood culture-negative infective endocarditis; ID ¼ infectious disease; i.m. ¼ intramuscular; i.v. ¼ intravenous; PVE ¼ prosthetic valve endocarditis.
aIf initial blood cultures are negative and there is no clinical response, consider BCNIE aetiology (see Section 7.10) and maybe surgery for molecular diagnosis and treatment, and
extension of the antibiotic spectrum to blood culture-negative pathogens (doxycycline, quinolones) must be considered.
bClass of recommendation.
cLevel of evidence.
dMonitoring of gentamicin or vancomycin dosages is as described in Tables 16 and 17.
Table 21 Criteria that determine suitability of
outpatient parenteral antibiotic therapy for infective






• Complications occur during this phase
• Preferred inpatient treatment during this phase
• Consider OPAT if: oral streptococci or  





• Consider OPAT if medically stable
• Do not consider OPAT if: HF, concerning  
 echocardiographic features, neurological signs, or  
 renal impairment 
Essential for 
OPAT
• Educate patient and staff
• Regular post-discharge evaluation (nurses 1/day,  
 physicianc in charge 1 or 2/week)d
• Prefer physician-directed programme, not home- 
 infusion model
HF ¼ heart failure; ID ¼ infectious disease; IE ¼ infective endocarditis; OPAT ¼
outpatient parenteral antibiotic therapy; PVE ¼ prosthetic valve endocarditis.
aFor other pathogens, consultation with an ID specialist is recommended.
bFor patients with late PVE, consultation with an ID specialist is recommended.
cPreferably from the Endocarditis Team.
dGeneral physician can see the patient once a week, if needed.
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8. Main complications of left-sided
valve infective endocarditis and
their management
Surgical treatment is required in approximately half of the patients
with IE because of severe complications.54 Reasons to consider
early surgery in the active phase (i.e. while the patient is still receiv-
ing antibiotic treatment) are to avoid progressive HF and irrevers-
ible structural damage caused by severe infection and to prevent
systemic embolism.6,54,115,208 –210 On the other hand, surgical ther-
apy during the active phase of the disease is associated with signifi-
cant risk. Surgery is justified in patients with high-risk features that
make the possibility of cure with antibiotic treatment unlikely and
who do not have co-morbid conditions or complications that
make the prospect of recovery remote. Age per se is not a contra-
indication to surgery.211
Early consultation with a cardiac surgeon is recommended in or-
der to determine the best therapeutic approach. Identification of pa-
tients requiring early surgery is frequently difficult and is an
important objective of the ‘Heart Team’. Each case must be indivi-
dualized and all factors associated with increased risk identified at
the time of diagnosis. Frequently the need for surgery will be deter-
mined by a combination of several high-risk features.211
In some cases, surgery needs to be performed on an emergency
(within 24 h) or urgent (within a few days, ,7 days) basis, irrespect-
ive of the duration of antibiotic treatment. In other cases, surgery
can be postponed to allow 1 or 2 weeks of antibiotic treatment un-
der careful clinical and echocardiographic observation before an
elective surgical procedure is performed.63,115 The three main indi-
cations for early surgery in IE are HF, uncontrolled infection and
prevention of embolic events212– 216 (Table 22).
8.1 Heart failure
8.1.1 Heart failure in infective endocarditis
HF is the most frequent complication of IE and represents the most
common indication for surgery in IE.54 HF is observed in 42–60% of
cases of NVE and is more often present when IE affects the aortic
rather than the mitral valve.111,208,212 HF is mainly caused by new
Table 22 Indications and timing of surgery in left-sided valve infective endocarditis (native valve endocarditis and
prosthetic valve endocarditis)
Indications for surgery Timinga Classb Levelc Ref.d
1. Heart failure
Aortic or mitral NVE or PVE with severe acute regurgitation, obstruction or fistula causing refractory





Aortic or mitral NVE or PVE with severe regurgitation or obstruction causing symptoms of HF or











Infection caused by fungi or multiresistant organisms Urgent/
elective
I C




PVE caused by staphylococci or non-HACEK gram-negative bacteria Urgent/
elective
IIa C
3. Prevention of embolism
Aortic or mitral NVE or PVE with persistent vegetations .10 mm after one or more embolic





Aortic or mitral NVE with vegetations .10 mm, associated with severe valve stenosis or
regurgitation, and low operative risk
Urgent
IIa B 9
Aortic or mitral NVE or PVE with isolated very large vegetations (.30 mm) Urgent IIa B 113




HACEK ¼ Haemophilus parainfluenzae, Haemophilus aphrophilus, Haemophilus paraphrophilus, Haemophilus influenzae, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis,
Eikenella corrodens, Kingella kingae and Kingella denitrificans; HF ¼ heart failure; IE ¼ infective endocarditis; NVE ¼ native valve endocarditis; PVE ¼ prosthetic valve endocarditis.




eSurgery may be preferred if a procedure preserving the native valve is feasible.
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or worsening severe aortic or mitral regurgitation, although intra-
cardiac fistulae213 and, more rarely, valve obstruction may also
lead to HF.
Valvular regurgitation in native IE may occur as a result of mitral
chordal rupture, leaflet rupture (flail leaflet), leaflet perforation or
interference of the vegetation mass with leaflet closure. A particular
situation is infection of the anterior mitral leaflet secondary to an in-
fected regurgitant jet of a primary aortic IE.214 Resultant aneurysm
formation on the atrial side of the mitral leaflet may later lead to
mitral perforation.215
Clinical presentation of HF may include dyspnoea, pulmonary oe-
dema and cardiogenic shock.111,120 Among the large ICE Prospect-
ive Cohort Study patients with HF and IE, 66% were in New York
Heart Association class III or IV.216 In addition to clinical findings,
TTE is of crucial importance for initial evaluation and follow-up.64
Valve perforation, secondary mitral lesions and aneurysms are
best assessed using TOE.64,65,214 Echocardiography is also useful
to evaluate the haemodynamic consequences of valvular dysfunc-
tion, measurement of pulmonary artery pressure, detection of peri-
cardial effusion and assessment and monitoring of left ventricular
systolic function and left and right heart filling pressures.64 B-type
natriuretic peptide has potential use in the diagnosis and monitoring
of HF in IE.217 Both elevated levels of cardiac troponins and B-type
natriuretic peptide are associated with adverse outcomes in
IE.218,219 Moderate to severe HF is the most important predictor
of in-hospital, 6-month and 1-year mortality.52,109,111,117,208
8.1.2 Indications and timing of surgery in the presence of
heart failure in infective endocarditis (Table 22)
Identification of surgical candidates and timing of surgery decisions
should preferably be made by the Endocarditis Team.118 The pres-
ence of HF indicates surgery in the majority of patients with IE and is
the principal indication for urgent surgery.115,124 Surgery is indicated
in patients with HF caused by severe aortic or mitral regurgitation,
intracardiac fistulae or valve obstruction caused by vegetations. Sur-
gery is also indicated in patients with severe acute aortic or mitral
regurgitation without clinical HF but with echocardiographic signs
of elevated left ventricular end-diastolic pressure (e.g. premature
closure of the mitral valve), high left atrial pressure or moderate
to severe pulmonary hypertension. These rules apply in both NVE
and PVE.37,220,221
Surgery must be performed on an emergency basis, irrespective
of the status of infection, when patients are in persistent pul-
monary oedema or cardiogenic shock despite medical therapy.63
Surgery must be performed on an urgent basis when HF is less
severe. Urgent surgery should also be performed in patients
with severe aortic or mitral insufficiency with large vegetations,
even without HF.9
In patients with well-tolerated (New York Heart Association
class I or II) severe valvular regurgitation and no other reasons for
surgery, medical management with antibiotics under strict clinical
and echocardiographic observation is a good option, although early
surgery may be an option in selected patients at low risk for surgery.
Elective surgery should be considered depending on the tolerance
of the valve lesion and according to the recommendations of the
ESC Guidelines on the management of valvular heart disease.55
In summary, HF is the most frequent and among the most severe
complications of IE. Unless severe co-morbidity exists, the pres-
ence of HF is an indication for early surgery in NVE and PVE,
even in patients with cardiogenic shock.
8.2 Uncontrolled infection
Uncontrolled infection is one of the most feared complications of IE
and is the second most frequent cause for surgery.54 Uncontrolled
infection is considered to be present when there is persisting infec-
tion and when there are signs of locally uncontrolled infection. Infec-
tion due to resistant or very virulent organisms often results in
uncontrolled infection.
8.2.1 Persisting infection
The definition of persisting infection is arbitrary and consists of fever
and persisting positive cultures after 7–10 days of antibiotic treat-
ment. Persisting fever is a frequent problem observed during treat-
ment of IE. Usually, temperature normalizes within 7–10 days under
specific antibiotic therapy. Persisting fever may be related to several
factors, including inadequate antibiotic therapy, resistant organisms,
infected lines, locally uncontrolled infection, embolic complications
or extracardiac site of infection and adverse reaction to antibiotics.3
Management of persisting fever includes replacement of i.v. lines, re-
peat laboratory measurements, blood cultures, echocardiography,
and the search for an intracardiac or extracardiac focus of infection.
8.2.2 Perivalvular extension in infective endocarditis
Perivalvular extension of IE is the most frequent cause of uncon-
trolled infection and is associated with a poor prognosis and high
likelihood of the need for surgery. Perivalvular complications in-
clude abscess formation, pseudoaneurysms and fistulae (defined in
Table 11).223,224
Perivalvular abscess is more common in aortic IE (10–40% in
NVE)3,225 – 227 and is frequent in PVE (56–100%).3,6 In mitral IE, peri-
valvular abscesses are usually located posteriorly or laterally.228 In
aortic IE, perivalvular extension occurs most frequently in the
mitral-aortic intervalvular fibrosa.229 Serial echocardiographic stud-
ies have shown that abscess formation is a dynamic process, starting
with aortic root wall thickening and extending to the development
of fistulae.229 In one study, the most important risk factors for peri-
valvular complications were prosthetic valve, aortic location and in-
fection with CoNS.230
Pseudoaneurysms and fistulae are severe complications of IE and
are frequently associated with very severe valvular and perivalvular
damage.213,231 – 233 The frequency of fistula formation in IE has been
reported to be 1.6%, with S. aureus being the most commonly asso-
ciated organism (46%).233
Despite high rates of surgery in this population (87%), hospital
mortality remains high (41%).213,233,234 Other complications due
to major extension of infection are less frequent and may include
ventricular septal defect, third-degree atrio-ventricular block and
acute coronary syndrome.223,224,234
Perivalvular extension should be suspected in cases with persist-
ent unexplained fever or new atrio-ventricular block. Therefore an
electrocardiogram should be performed frequently during continu-
ing treatment, particularly in aortic IE. TOE, MSCT and PET/CT103
are particularly useful for the diagnosis of perivalvular complications,
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while the sensitivity of TTE is ,50%225– 228 (see section 5). Indeed,
perivalvular extension is frequently discovered on a systematic TOE.
However, small abscesses can be missed, even using TOE, particu-
larly those in a mitral location when there is co-existent annular
calcification.101
8.2.3 Indications and timing of surgery in the presence of
uncontrolled infection in infective endocarditis (Table 22)
The results of surgery when the reason for the procedure is uncon-
trolled infection are worse than when surgery is performed for
other reasons.124,235
8.2.3.1 Persistent infection
In some cases of IE, antibiotics alone are insufficient to eradicate the
infection. Surgery has been indicated when fever and positive blood
cultures persist for several days (7–10 days) despite an appropriate
antibiotic regimen and when extracardiac abscesses (splenic, verte-
bral, cerebral or renal) and other causes of fever have been
excluded. However, the best timing for surgery in this difficult situ-
ation is unclear. Recently it has been demonstrated that persistent
blood cultures 48–72 h after initiation of antibiotics are an independ-
ent risk factor for hospital mortality.123 These results suggest that sur-
gery should be considered when blood cultures remain positive after
3 days of antibiotic therapy, after the exclusion of other causes of per-
sistent positive blood cultures (adapted antibiotic regimen).
8.2.3.2 Signs of locally uncontrolled infection
Signs of locally uncontrolled infection include increasing vegetation
size, abscess formation, false aneurysms, and the creation of fistu-
lae.213,236,237 Persistent fever is also usually present and surgery is
recommended as soon as possible. Rarely when there are no other
reasons for surgery and fever is easily controlled with antibiotics,
small abscesses or false aneurysms can be treated conservatively un-
der close clinical and echocardiographic follow-up.
8.2.3.3 Infection by microorganisms at low likelihood of being controlled
by antimicrobial therapy
Surgery is indicated in fungal IE,238,239 in cases of multiresistant or-
ganisms (e.g. MRSA or vancomycin-resistant enterococci) or in the
rare infections caused by Gram-negative bacteria. Surgery should
also be considered in PVE caused by staphylococci or non-HACEK
Gram-negative bacteria. In NVE caused by S. aureus, surgery is indi-
cated if a favourable early response to antibiotics is not
achieved161,240,241 (Table 22). Finally, surgery should be performed
in patients with PVE and S. aureus infection.
In summary, uncontrolled infection is most frequently related to
perivalvular extension or ‘difficult-to-treat’ organisms. Unless se-
vere co-morbidity exists, the presence of locally uncontrolled in-
fection is an indication for early surgery in patients with IE.
8.3 Prevention of systemic embolism
8.3.1 Embolic events in infective endocarditis
Embolic events are a frequent and life-threatening complication of IE
related to the migration of cardiac vegetations. The brain and spleen
are the most frequent sites of embolism in left-sided IE, while pul-
monary embolism is frequent in native right-sided and pacemaker
lead IE. Stroke is a severe complication and is associated with
increased morbidity and mortality.105 Conversely, embolic events
may be totally silent in 20–50% of patients with IE, especially those
affecting the splenic or cerebral circulation, and can be diagnosed by
non-invasive imaging.83,85,242 Thus systematic abdominal and cere-
bral CT scanning may be helpful. However, contrast media should
be used with caution in patients with renal impairment or haemo-
dynamic instability because of the risk of worsening renal impair-
ment in combination with antibiotic nephrotoxicity.
Overall, embolic risk is very high in IE, with embolic events occur-
ring in 20–50% of patients.72,242 – 249 However, the risk of new
events (occurring after initiation of antibiotic therapy) is only 6–
21%.72,115,243 A study from the ICE group250 demonstrated that
the incidence of stroke in patients receiving appropriate antimicro-
bial therapy was 4.8/1000 patient-days in the first week of therapy,
falling to 1.7/1000 patient-days in the second week, and further
thereafter.
8.3.2 Predicting the risk of embolism
Echocardiography plays a key role in predicting embolic
events,72,115,246 –252 although prediction remains difficult in the indi-
vidual patient. Several factors are associated with increased risk of
embolism, including the size and mobility of vegetations,72,242,246–253
the location of the vegetation on the mitral valve,72,246 – 249 the in-
creasing or decreasing size of the vegetation under antibiotic ther-
apy,72,253 particular microorganisms (S. aureus,72 S. bovis,254 Candida
spp.), previous embolism,72 multivalvular IE246 and biological mar-
kers.255 Among these, the size and mobility of the vegetations are
the most potent independent predictors of a new embolic event.253
Patients with vegetations.10 mm in length are at higher risk of em-
bolism,58,253 and this risk is even higher in patients with larger
(.15 mm) and mobile vegetations, especially in staphylococcal IE
affecting the mitral valve.219 A recent study113 found that the risk
of neurological complications was particularly high in patients with
very large (.30 mm length) vegetations.
Several factors should be taken into account when assessing em-
bolic risk. In a recent study of 847 patients with IE, the 6-month in-
cidence of new embolism was 8.5%.222 Six factors (age, diabetes,
atrial fibrillation, previous embolism, vegetation length and
S. aureus infection) were associated with an increased embolic risk
and were used to create an ‘embolic risk calculator’.222
Whatever the risk factors observed in an individual patient, it must
be re-emphasized that the risk of new embolism is highest during the
first days following initiation of antibiotic therapy and rapidly de-
creases thereafter, particularly beyond 2 weeks,58,72,243,250 although
some risk persists indefinitely while vegetations remain present, par-
ticularly for very large vegetations.113 For this reason, the benefits of
surgery to prevent embolism are greatest during the first 2 weeks of
antibiotic therapy, when embolic risk peaks.
8.3.3 Indications and timing of surgery to prevent
embolism in infective endocarditis (Table 22)
Avoiding embolic events is difficult since the majority occur before
admission.222 The best means to reduce the risk of an embolic event
is the prompt institution of appropriate antibiotic therapy.38 While
promising,256,257 the addition of antiplatelet therapy did not reduce
the risk of embolism in the only published randomized study.258
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The exact role of early surgery in preventing embolic events re-
mains controversial. In the Euro Heart Survey, vegetation size was
one of the reasons for surgery in 54% of patients with NVE and in
25% of those with PVE,54 but was rarely the only reason. The value
of early surgery in an isolated large vegetation is controversial. A re-
cent randomized trial demonstrated that early surgery in patients
with large vegetations significantly reduced the risk of death and em-
bolic events compared with conventional therapy.9 However, the
patients studied were at low risk and there was no significant differ-
ence in all-cause mortality at 6 months in the early surgery and
conventional-treatment groups.
Finally, the decision to operate early for prevention of embolism
must take into account the presence of previous embolic events,
other complications of IE, the size and mobility of the vegetation,
the likelihood of conservative surgery and the duration of antibiotic
therapy.115 The overall benefits of surgery should be weighed
against the operative risk and must consider the clinical status and
co-morbidity of the patient.
The main indications and timing of surgery to prevent embolism
are given in Table 22. Surgery is indicated in patients with persisting
vegetations .10 mm after one or more clinical or silent embolic
events despite appropriate antibiotic treatment.58 Surgery may be
considered in patients with large (.15 mm) isolated vegetations
on the aortic or mitral valve, although this decision is more difficult
and must be very carefully individualized according to the probabil-
ity of conservative surgery.58
Surgery undertaken for the prevention of embolism must be per-
formed very early, during the first few days following initiation of
antibiotic therapy (urgent surgery), as the risk of embolism is highest
at this time.58,72
In summary, embolism is very frequent in IE, complicating 20–
50% of cases of IE, but falling to 6–21% after initiation of antibiot-
ic therapy. The risk of embolism is highest during the first 2 weeks
of antibiotic therapy and is clearly related to the size andmobility
of the vegetation, although other risk factors exist. The decision
to operate early to prevent embolism is always difficult and spe-
cific for the individual patient. Governing factors include the size
and mobility of the vegetation, previous embolism, type of micro-
organism and duration of antibiotic therapy.
9. Other complications of infective
endocarditis
9.1 Neurological complications
Symptomatic neurological complications occur in 15–30% of patients
with IE and are mainly the consequence of embolism from vegeta-
tions.110,113,259 Neurological manifestations occur before or at IE diag-
nosis in a majority of cases, but new or recurrent events can also take
place later in the course of IE. Clinical presentation is variable and may
include multiple symptoms or signs in the same patient, but focal signs
predominate and ischaemic strokes are most commonly diagnosed.
Transient ischaemic attack, intracerebral or subarachnoidal haemor-
rhage, brain abscess, meningitis and toxic encephalopathy are also
seen, and firm evidence supports that additional clinically silent cere-
bral embolisms occur in 35–60% of IE patients.83,85,90 S. aureus IE is
more frequently associated with neurological complications compared
with IE caused by other bacteria. Vegetation length and mobility also
correlate with embolic tendency.88,242 Neurological complications are
associated with an excess mortality, as well as sequelae, particularly in
the case of stroke.113,259 Rapid diagnosis and initiation of appropriate
antibiotics are of major importance to prevent a first or recurrent
neurological complication.250 Early surgery in high-risk patients is the
second mainstay of embolism prevention, while antithrombotic drugs
have no role (see section 12.7).
Successful management of IE requires a combined medical and
surgical approach in a substantial proportion of patients. Following
a neurological event, the indication for cardiac surgery often remains
or is strengthened, but must be balanced with perioperative risk and
postoperative prognosis. Randomized studies are not possible and
cohort studies suffer from bias that can only be partly compensated
for by statistical methods.115,260 – 262 However, the risk of post-
operative neurological deterioration is low after a silent cerebral
emboli or transient ischaemic attack, and surgery is recommended
without delay if an indication remains.105 After an ischaemic stroke,
cardiac surgery is not contraindicated unless the neurological progno-
sis is judged too poor.263 Evidence regarding the optimal time interval
between stroke and cardiac surgery is conflicting, but recent data fa-
vour early surgery.9,115 If cerebral haemorrhage has been excluded by
cranial CT and neurological damage is not severe (i.e. coma), surgery
indicated for HF, uncontrolled infection, abscess or persistent high
embolic risk should not be delayed and can be performed with a
low neurological risk (3–6%) and good probability of complete
neurological recovery.105,263 Conversely, in cases with intracranial
haemorrhage, neurological prognosis is worse and surgery should
generally be postponed for at least 1 month,264,265 although one re-
cent study has reported a relatively low risk of neurological deterior-
ation in IE patients undergoing surgery within 2 weeks after an
intracranial haemorrhage.266 The Task Force has thus decided to
adapt the level of evidence to a class IIa. If urgent cardiac surgery is
needed, close cooperation with the neurosurgical team and the
Endocarditis Team is mandatory. Table 23 and Figure 4 summarize
the recommended management of neurological complications in IE.
Cerebral imaging is mandatory for any suspicion of neurological
complication of IE. CT scanning, with or without contrast agent, is
most often performed. The higher sensitivity of MRI, with or with-
out contrast gadolinium enhancement, allows for better detection
and analysis of cerebral lesions in patients with neurological symp-
toms, and this may have an impact on the timing of surgery89 (see
section 5). In patients without neurological symptoms, cerebral
MRI often detects lesions that may change the therapeutic strategy;
in particular, the indications and timing of surgery.85,90 Cerebral MRI
often detects microbleeds (round T2* hypointensities with a diam-
eter ≤10 mm) in patients with IE. The lack of association with par-
enchymal haemorrhage and the absence of postoperative
neurological complications in patients with microbleeds suggest
that microbleeds should not be interpreted as active bleeding and
should not lead to postponed surgery when this is indicated.89,90
In summary, symptomatic neurological events develop in 15–30%
of all patients with IE and additional silent events are frequent.
Stroke (ischaemic and haemorrhagic) is associated with excess
mortality. Rapid diagnosis and initiation of appropriate antibiotics
are ofmajor importance to prevent a first or recurrent neurological
complication. After a first neurological event, cardiac surgery, if
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indicated, is generally not contraindicated, except when extensive
brain damage or intracranial haemorrhage is present.
9.2 Infectious aneurysms
Infectious (mycotic) aneurysms result from septic arterial embolism
to the intraluminal space or vasa vasorum or from subsequent spread
of infection through the intimal vessels. Infectious aneurysms are typ-
ically thin walled and friable and, as such, exhibit a high tendency to
rupture and haemorrhage. No predictor of rupture has been identi-
fied and, in contrast to non-infectious aneurysms, size does not ap-
pear to be a reliable predictor of potential rupture.268,269
An intracranial location is most common and the reported fre-
quency of 2–4% is probably an underestimation since some infec-
tious aneurysms are clinically silent.267,270 Early detection and
treatment of infectious aneurysms is essential given the high morbid-
ity and mortality rate secondary to rupture. Clinical presentation is
highly variable (i.e. focal neurological deficit, headache, confusion,
seizures), so imaging should be systematically performed to detect
intracranial infectious aneurysms in any case of IE with neurological
symptoms.268
Cerebral CT and MRI both reliably diagnose infectious aneurysms
with good sensitivity and specificity.271 However, conventional angi-
ography remains the gold standard and should be performed when
non-invasive techniques are negative and suspicion remains.267
Owing to the lack of randomized trials, there is no widely accepted
standard management for infectious aneurysms. Thus management
should be provided by an Endocarditis Team and tailored to the indi-
vidual patient. Some infectious aneurysms may resolve during anti-
biotic treatment, while others require surgical or endovascular
intervention depending on the occurrence of rupture and the loca-
tion in the artery bed, as well as the clinical status of the patient.268,269
Regarding intracranial infectious aneurysms, ruptured aneurysms
must be treated immediately by surgical or endovascular procedures.
Unruptured infectious aneurysms should be followed by serial cere-
bral imaging under antibiotic therapy. If the size of the aneurysm de-
creases or resolves completely, surgical or endovascular intervention
is usually unnecessary. However, if the size of the aneurysm increases
or remains unchanged, it is likely that the patient will require interven-
tion. On the other hand, if the infectious aneurysm is voluminous and
symptomatic, neurosurgery or endovascular therapy is recom-
mended.272 Finally, if early cardiac surgery is required, preoperative
endovascular intervention might be considered before the proced-
ure, depending on associated cerebral lesions, the haemodynamic sta-
tus of the patient and the risk of the procedure.
9.3 Splenic complications
Splenic infarcts are common and very often asymptomatic. Persist-
ent or recurrent fever, abdominal pain and bacteraemia suggest the



















• Cerebral CT scan / MRI
• TTE / TOE
CT = computed tomography; IE = infective endocarditis; MRI = magnetic resonance imaging; 
TOE = transoesophageal echocardiography; TTE = transthoracic echocardiography.
Figure 4 Therapeutic strategies for patients with infective endo-
carditis and neurological complications.
Table 23 Management of neurological
complications of infective endocarditis
Recommendations Classa Levelb Ref.c
After a silent embolism or transient
ischaemic attack, cardiac surgery, if





Neurosurgery or endovascular therapy
is recommended for very large, enlarging




surgery should generally be postponed
for ≥1 month
IIa B 264–266
After a stroke, surgery indicated for HF,
uncontrolled infection, abscess, or
persistent high embolic risk should be
considered without any delay as long as
coma is absent and the presence of
cerebral haemorrhage has been
excluded by cranial CT or MRI
IIa B 9,263
Intracranial infectious aneurysms should
be looked for in patients with IE and
neurological symptoms. CT or MR
angiography should be considered for
diagnosis. If non-invasive techniques are
negative and the suspicion of
intracranial aneurysm remains,





CT ¼ computed tomography; HF ¼ heart failure; IE ¼ infective endocarditis;











splenic emboli are common, splenic abscesses are rare. Persistent or
recurrent fever and bacteraemia suggest the diagnosis. These pa-
tients should be evaluated by abdominal CT, MRI or ultrasound. Re-
cently PET has proved useful for the diagnosis of splenic metastasic
infection in patients with IE.273 Treatment consists of appropriate
antibiotic regimens. Splenectomy may be considered for splenic
rupture or large abscesses, which respond poorly to antibiotics
alone, and should be performed before valvular surgery unless the
latter is urgent. Rarely, splenectomy and valvular surgery are per-
formed during the same operative time. Percutaneous drainage is
an alternative for high-risk surgical candidates.274,275
9.4 Myocarditis and pericarditis
Cardiac failure may be due to myocarditis, which is frequently asso-
ciated with abscess formation or immune reaction. Ventricular arrhyth-
mias may indicate myocardial involvement and imply a poor prognosis.
Myocardial involvement is best assessed using TTE and cardiac MRI.
The inflammatory response, HF, periannular complications or in-
fection itself can cause pericardial effusion, which could be a sign of
more severe IE. Rarely, ruptured pseudoaneurysms or fistulae may
communicate with the pericardium, with dramatic and often fatal
consequences. Purulent pericarditis is rare and may necessitate sur-
gical drainage.276,277
9.5 Heart rhythm and conduction
disturbances
Conduction disorders are uncommon complications of IE. Accord-
ing to data from patient registries, their frequency is between 1%
and 15% of cases and their presence is associated with worse prog-
nosis and higher mortality.278
Conduction abnormalities (mainly first-, second-, and third-
degree atrio-ventricular blocks, rarely bundle branch blocks) are
due to spread of the infection beyond the endocardium, from valves
to the conduction pathways, and are generally associated with peri-
valvular complications. Complete atrio-ventricular block is most of-
ten associated with involvement of the left-sided valves (aortic, 36%;
mitral, 33%).278 This is because of the anatomical relationship with
the atrio-ventricular node, which is close to the non-coronary aortic
cusp and the anterior mitral leaflet. In a study of patients with IE and
complete atrio-ventricular block, pathology workup revealed the
presence of an infection, frequently accompanied by abscesses
and fistulae, affecting the conduction pathways; in cases of paroxys-
mal atrio-ventricular block, inflammation was observed at this level,
which would explain the reversibility of the event.279
The occurrence of conduction abnormalities during electrocar-
diographic monitoring in patients with endocarditis can therefore
alert physicians to the appearance of perivalvular complications.
In the case of embolization of vegetation fragments into a coron-
ary artery, the resulting myocardial ischaemia can be the substrate
for the onset of tachyarrhythmias.280
Atrial fibrillation can be observed in patients with IE and may be
present before IE or occur as a complication of IE. Atrial fibrillation
has been reported to be more frequent in the elderly and to be asso-
ciated with a poor prognosis.281 More recently, in a large prospective
series of IE, atrial fibrillation was found to be associated with an
increased embolic risk, as were other factors (age, diabetes, previous
embolism, vegetation length and S. aureus infection).222 Consequently,
atrial fibrillation has the potential to increase the risk of both congest-
ive HF and embolism in IE. However, there is no specific study on this
situation and no international consensus for the care of these patients.
The management of anticoagulation therapy in these patients should
be taken on an individual basis by the Endocarditis Team.
9.6 Musculoskeletal manifestations
Musculoskeletal symptoms (arthralgia, myalgia, back pain) are fre-
quent during IE.282,283 Rheumatological manifestations may be the
first manifestations of IE and can delay its diagnosis, especially
when classic manifestations are less evident and a variety of anti-
bodies (i.e. positive antineutrophil cytoplasmic antibody test) in-
duced by infections284,285 are present. Arthralgia occurs in about
10% of patients, while myalgia is present in 12–15%.282,286 Back
pain is observed in about 13% of cases, and lumbar pain is the
most common symptom in patients with IE and vertebral osteomye-
litis.282,283,287,288 Peripheral arthritis occurs in about 14% of
cases.282 The prevalence of spondylodiscitis in patients with IE is
about 1.8–15%.282 Pyogenic vertebral osteomyelitis occurs in
4.6–19% of IE patients with a high incidence of streptococcal and
staphylococcal bacteraemia.283,287 IE can complicate or be compli-
cated by pyogenic osteomyelitis. The prevalence of IE in vertebral
osteomyelitis is higher288,289 in the presence of Streptococcus viridans
IE. CT, but preferably MRI, of the spine or whole-body 18F-FDG-
PET/CT290 should be performed in IE patients with back or bone
pain. Conversely, echocardiography should be performed in
patients with a definite diagnosis of pyogenic spondylodiscitis/
osteomyelitis and underlying cardiac conditions predisposing to IE.
In definite spondylodiscitis and osteomyelitis, prolonged antibiot-
ic therapy is generally required until no signs of inflammatory activity
are detected by 18FDG PET/CT or MRI. Other musculoskeletal
manifestations are less common in IE and include sacroiliitis in about
1% of cases, a condition mimicking polymyalgia rheumatica with pain
and morning stiffness of the shoulders and hips, proximal muscle
weakness in about 0.9% of cases and cutaneous leucocytoclastic vas-
culitis (purpuric skin lesions) in 3.6% of cases.282,289
9.7 Acute renal failure
Acute renal failure is a common complication of IE and may worsen
the prognosis of IE. The onset of renal dysfunction is independently
associated with increased risk of in-hospital death291,292 and post-
operative events.293
Acute renal dysfunction occurs in about 6–30% of pa-
tients.291,292,294,295 Causes are often multifactorial:296,297 (i) immune
complex and vasculitic glomerulonephritis; (ii) renal infarction,
mostly due to septic emboli, occurring at any time during the course
of the disease; (iii) haemodynamic impairment in cases with HF or
severe sepsis or after cardiac surgery; (iv) antibiotic toxicity (acute
interstitial nephritis), notably related to aminoglycosides, vancomy-
cin (synergistic toxicity with aminoglycosides) and even high-dose
penicillin; and (v) nephrotoxicity of contrast agents used for imaging
purposes.
Haemodialysis may be required in some patients with advanced
renal failure and is associated with high mortality.295 Acute renal
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failure of a milder degree is often reversible.295 To mitigate this com-
plication, antibiotic doses should be adjusted for creatinine clear-
ance with careful monitoring of serum levels (aminoglycosides and
vancomycin). Imaging with nephrotoxic contrast agents should be
avoided when possible in patients with haemodynamic impairment
or previous renal insufficiency.
10. Surgical therapy: principles
and methods
10.1 Operative risk assessment
Few studies have evaluated the utility of operative risk scores in the
setting of IE. Although EuroSCORE II is frequently used,298 it was de-
veloped and validated predominantly for coronary artery bypass
grafting and valve surgery. Risk scores specific to IE surgery have
been developed: (i) from the Society of Thoracic Surgeons database
using 13 617 patients299 and (ii) an additional NVE risk score from a
single centre using 440 patients by De Feo et al.300 A study com-
pared the prognostic utility of these contemporary risk scores for
mortality and morbidity after IE surgery in 146 patients.301 Here, al-
though EuroSCORE II discriminated mortality and postoperative
morbidity (in particular, stroke), the Society of Thoracic Surgeons
endocarditis score and the De Feo et al. score300 performed better
at predicting operative mortality after surgery for active IE. How-
ever, the relevance of these findings is limited by the small number
of patients involved. Similar to previous studies, preoperative use of
inotropes or an intra-aortic balloon pump, prior coronary artery by-
pass surgery and renal failure requiring dialysis were independent
predictors of operative and long-term mortality.
Finally, although no single operative risk score is perfect, pre-
operative assessment of operative risk is of utmost importance.
Although the theoretical indications for surgery in IE are clear
(Table 22), their practical application relies largely on the clinical
status of the patient, the patient’s co-morbidities and the patient’s
operative risk.
10.2 Preoperative and perioperative
management
10.2.1 Coronary angiography
Coronary angiography is recommended according to the ESC
Guidelines on the management of valvular heart disease55 in men
.40 years, in post-menopausal women and in patients with at least
one cardiovascular risk factor or a history of coronary artery dis-
ease. Exceptions arise when there are aortic vegetations that may
be dislodged during catheterization or when emergency surgery is
necessary. In these situations, high-resolution CT may be used to
rule out significant coronary artery disease in haemodynamically
stable patients.55
10.2.2 Extracardiac infection
If a primary focus of infection likely to be responsible for IE has been
identified, it must be eradicated before cardiac surgical intervention
unless valve surgery is urgent. In any case, it should be eradicated
before the end of antibiotic therapy.
10.2.3 Intraoperative echocardiography
Intraoperative TOE is most useful to determine the exact location
and extent of infection, guide surgery, assess the result and help in
early postoperative follow-up.73
10.3 Surgical approach and techniques
The two primary objectives of surgery are total removal of infected
tissues and reconstruction of cardiac morphology, including repair
or replacement of the affected valve(s).
Where infection is confined to the valve cusps or leaflets, any
method to repair or replace the valve may be used. However, valve
repair is favoured whenever possible, particularly when IE affects the
mitral or tricuspid valve without significant destruction.302 Perfora-
tions in a single valve cusp or leaflet may be repaired with an untreat-
ed or glutaraldehyde-treated autologous or bovine pericardial
patch. Isolated or multiple ruptured chordae may be replaced by
polytetrafluoroethylene neo-chordae.
More extensive destruction of a single leaflet or the presence of
an abscess is not necessarily a contraindication for valve repair.302
Rather, intraoperative assessment of the valve after debridement
is of paramount importance in order to evaluate whether the re-
maining tissue is of sufficient quality to achieve a durable repair.
The need for a patch to achieve a competent valve, whether pericar-
dial, tricuspid autograft or a flipped-over mitral patch, has not been
associated with worse results in terms of recurrence of IE or mitral
regurgitation when performed by experienced surgeons.303
To avoid paravalvular leaks in complex cases with locally uncon-
trolled infection, total excision of infected and devitalized tissue
should be followed by valve replacement and repair of associated
defects to secure valve fixation.304
Mechanical and biological prostheses have similar operative mor-
tality.305 Therefore the Task Force does not favour any specific valve
substitute but recommends a tailored approach for each individual
patient and clinical situation. The use of foreign material should be
kept to a minimum. Small abscesses can be closed directly, but larger
cavities should be allowed to drain into the pericardium or
circulation.
In mitral valve IE, successful valve repair can be achieved by ex-
perienced teams in up to 80% of patients, but such results may
not be matched in non-specialist centres.306 Moreover, although
surgery may be deferred if control of the infection by antibiotic ther-
apy appears evident in the absence of cardiac failure, early operation
has been associated in recent reports with a repair rate of 61–80%
and improved in-hospital and long-term survival.209,210,302,303,307 Re-
sidual mitral regurgitation should be assessed using intraoperative
TOE. Mitral subannular, annular or supraannular tissue defects are
preferably repaired with autologous or bovine pericardium, a pros-
thetic valve then being secured to the reconstructed/reinforced an-
nulus, if necessary. The choice of technique depends on the vertical
extension of the lesion/tissue defect.308 –310 The use of mitral valve
homografts and pulmonary autografts (Ross II procedure) has been
suggested,311,312 but their application is limited by poor availability
and difficulty of the surgical technique, and the results have not
been consistent.
In aortic IE, replacement of the aortic valve using a mechanical or
biological prosthesis is the technique of choice. Nevertheless, in
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centres with great expertise, aortic valve repair in IE can be achieved
in up to 33% of patients. However, experience with aortic valve re-
pair in this setting is still very limited and there is no evidence that
repair is associated with improved outcomes compared with re-
placement.313,314 Owing to their natural biocompatibility, the use
of cryopreserved or sterilized homografts has been suggested to re-
duce the risk of persistent or recurrent infection, especially in the
presence of annular abscesses.315,316 It is expert opinion and stand-
ard strategy in many institutions that the use of a homograft is to be
favoured over valve prostheses, particularly in the presence of root
abscess.316,317 However, mechanical prostheses and xenografts
have led to similar results in terms of persistent or recurrent infec-
tion and survival if associated with complete debridement of annular
abscesses.313,318 Homografts or stentless xenografts may be pre-
ferred in PVE or in cases where there is extensive aortic root de-
struction with aorto-ventricular discontinuity.315,319 The anterior
mitral leaflet of the aortic homograft can be effectively used for re-
construction of the outflow tract. A monoblock aorto-mitral homo-
graft has been suggested as a surgical option for extensive bivalvular
IE.320 In experienced hands, the Ross procedure may be used in chil-
dren or adolescents to facilitate growth and in young adults for ex-
tended durability.321,322
Cardiac transplantation may be considered in extreme cases
where repeated operative procedures have failed to eradicate per-
sistent or recurrent PVE.323
10.4 Postoperative complications
Postoperative patient management should follow the usual recom-
mendations after valvular surgery324 but should also take into ac-
count the specificities of IE. Postoperative follow-up should be
particularly cautious given the in-hospital mortality of patients oper-
ated on for acute IE on an emergency or urgent basis, which ranges
from 10% to 20% in most series,1 and the increased risk of post-
operative complications.
Among the most frequent complications are severe coagulopathy
requiring treatment with clotting factors, re-exploration of the chest
for bleeding or tamponade, acute renal failure requiring haemodialy-
sis, stroke, low cardiac output syndrome, pneumonia and atrio-
ventricular block following radical resection of an aortic root ab-
scess with the need for pacemaker implantation.325 A preoperative
electrocardiogram demonstrating left bundle branch block predicts
the need for a postoperative permanent pacemaker.23 When a
patient does not survive surgery, the cause of death is often
multifactorial.325
11. Outcome after discharge:
follow-up and long-term prognosis
Following in-hospital treatment, the main complications include re-
currence of infection, HF, need for valve surgery and death.57,326,327
11.1 Recurrences: relapses and
reinfections
The actual risk of recurrence among survivors of IE varies between
2% and 6%.57,326 –332 Two main types of recurrence are distinguish-
able: relapse and reinfection. Although not systematically
differentiated in the literature, the term ‘relapse’ refers to a repeat
episode of IE caused by the same microorganism, while ‘reinfection’
describes an infection caused by a different microorganism.38 When
the same species is isolated during a subsequent episode of IE, there
is often uncertainty as to whether the repeat infection is a relapse of
the initial infection or a new infection (reinfection). In these cases,
molecular methods including strain-typing techniques should be
employed.8,38 When these techniques or the identity of both iso-
lates is unavailable, the timing of the second episode of IE may be
used to distinguish relapse from reinfection. Thus, although variable,
the time between episodes is usually shorter for relapse than for re-
infection. Generally speaking, a recurrence caused by the same spe-
cies within 6 months following the initial infection represents
relapse, whereas later events suggest reinfection.38 For these pur-
poses, storage of IE isolates for at least 1 year is recommended.8,38
Factors associated with an increased rate of relapse are listed in
Table 24. Relapses are most often due to insufficient duration of ori-
ginal treatment, suboptimal choice of initial antibiotics or a persist-
ent focus of infection. When the duration of therapy has been
insufficient or the choice of antibiotic incorrect, relapse should be
treated for a further 4–6 weeks depending on the causative micro-
organism and its antibiotic susceptibility (remembering that resist-
ance may develop in the meantime).
Patients with previous IE are at risk of reinfection,332 and prophy-
lactic measures should be very strict. Reinfection is more frequent in
IVDAs (especially in the year after the initial episode),332,333 in
PVE,334 in patients undergoing chronic dialysis326,332 and in those
with multiple risk factors for IE.8 Patients with reinfection are at
higher risk of death and need for valve replacement.325,332 Paravalv-
ular destruction is associated with a higher rate of recurrence and a
higher operative mortality.331 In a large series of surgically managed
NVE (358 cases), 21% had paravalvular destruction, and freedom
from recurrent PVE at 15 years was 78.9%.331
The type of valve implanted has no effect on the risk of recurrent
IE.325,331 Aortic valve and root replacement with a prosthetic
Table 24 Factors associated with an increased rate of
relapse
• Inadequate antibiotic treatment (agent, dose, duration)
• Resistant microorganisms, i.e. Brucella spp., Legionella spp., Chlamydia 
 spp., Mycoplasma spp., Mycobacterium spp., Bartonella spp., Coxiella 
 Burnetii, fungi 
• Polymicrobial infection in an IVDA
• Empirical antimicrobial therapy for BCNIE
• Periannular extension
• Prosthetic valve IE
• Persistent metastatic foci of infection (abscesses)
• Resistance to conventional antibiotic regimens
• Positive valve culture
• Persistence of fever at the seventh postoperative day
• Chronic dialysis
BCNIE ¼ blood culture-negative infective endocarditis; IE ¼ infective
endocarditis; IVDA ¼ intravenous drug abuser.
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conduit yields results similar to those for homograft root
replacement.335,336
11.2 Short-term follow-up
A first episode of IE should not be seen as an ending once the patient
has been discharged. Residual severe valve regurgitation may de-
compensate left ventricular function, or valve deterioration may
progress despite bacteriological cure, usually presenting with acute
HF. After completion of treatment, recommendations for surgery
follow conventional guidelines.55 As a consequence of increasing
rates of surgery during the active phase of infection, the need
for late valve surgery is low, ranging from 3% to 8% in recent
series.326– 328
Patients should be educated about the signs and symptoms of IE
after discharge. They should be aware that recurrence could occur
in IE and that new onset of fever, chills or other signs of infection
mandate immediate evaluation, including procurement of blood cul-
tures before empirical use of antibiotics. To monitor the develop-
ment of secondary HF, an initial clinical evaluation and baseline
TTE should be performed at the completion of antimicrobial ther-
apy and repeated serially, particularly during the first year of
follow-up.
Clinical follow-up should be done by the Endocarditis Team or by
a Heart Valve Clinic specialist.11,337 Regular clinical and echocardio-
graphic follow-up should be performed during the first year follow-
ing completion of treatment.8,12 This Task Force also recommends
to take blood samples (i.e. white cell count, CRP, etc.), and blood
cultures systematically at the initial visit, and otherwise if there is
clinical suspicion.
Good oral health maintenance, preventive dentistry and advice
about skin hygiene, including tattoos and skin piercing, are manda-
tory. Deficiencies in dental surveillance contribute to the continu-
ous gradual increase in the incidence of IE.30,337 This increase
underlines the need for repeating the principles of IE prevention
at each follow-up visit.
11.3 Long-term prognosis
In recent series, the crude long-term survival rates after the comple-
tion of treatment were estimated to be 80–90% at 1 year, 70–80%
at 2 years and 60–70% at 5 years.57,326 – 332 The main predictors
of long-term mortality are older age, co-morbidities, recurrences
and HF, especially when cardiac surgery cannot be
performed.57,327,330
Compared with an age- and sex-matched general population, pa-
tients surviving a first episode of IE have a significantly worse sur-
vival.57 This excess mortality is especially high within the first few
years after hospital discharge and can be explained by late complica-
tions such as HF, higher risk of recurrences and higher patient vul-
nerability.57,329 In fact, most recurrences and late cardiac surgeries
occurred during this period of time.57,328,329
In summary, recurrences are rare following IE and may be asso-
ciated with inadequate initial antibiotic therapy, resistant micro-
organisms, persistent focus of infection, i.v. drug abuse and
chronic dialysis. Patients with IE must be informed of the risk of
recurrence and educated about how to diagnose and prevent a
new episode of IE. The need for late valve surgery is low.
12. Management of specific
situations
12.1 Prosthetic valve endocarditis
PVE is the most severe form of IE and occurs in 1–6% of patients
with valve prostheses,338 with an incidence of 0.3–1.2% per patient-
year.216,233,339,340 PVE accounts for 10–30% of all cases of IE341 and
affects mechanical and bioprosthetic valves equally. PVE was ob-
served in 16% of cases of IE in a French survey,122 in 26% of cases
in the Euro Heart Survey54 and in 20% of 2670 patients with definite
IE in the ICE Prospective Cohort Study.340 PVE is still associated
with difficulties in diagnosis, determination of the optimal therapeut-
ic strategy and poor prognosis.
12.1.1 Definition and pathophysiology
Early PVE is defined as IE occurring within 1 year of surgery and late
PVE as IE occurring beyond 1 year, because of significant differences be-
tween the microbiological profiles observed before and after this time
point.3,342 However, this is an artificial distinction. What is important is
not the time from the valve replacement procedure to the onset of IE,
but whether IE is acquired perioperatively and which microorganism is
involved. A recent large, prospective, multicentre, international registry
reported that 37% of PVE cases were associated with nosocomial infec-
tion or non-nosocomial healthcare-associated infections in outpatients
with extensive healthcare contact.340
The pathogenesis of PVE differs according to both the type of
contamination and the type of prosthetic valve. In cases with peri-
operative contamination, the infection usually involves the junction
between the sewing ring and the annulus, leading to perivalvular ab-
scess, dehiscence, pseudo-aneurysms and fistulae.339,343,344 In late
PVE, additional mechanisms may exist. For example, in late biopros-
thetic PVE, infection is frequently located on the leaflets of the pros-
thesis, leading to vegetations, cusp rupture and perforation. PVE has
recently been reported after transcatheter aortic bioprosthetic
valve implantation, which should be managed in the same manner
as other prosthetic valves.345,346 The risk of prosthetic valve im-
plantation endocarditis increases with the use of orotracheal intub-
ation and a self-expandable valve system.
The consequence of PVE is usually new prosthetic regurgitation. Less
frequently, large vegetations may cause prosthetic valve obstruction,
which can be diagnosed by TOE and sometimes by TTE or fluoroscopy.
12.1.2 Diagnosis
Diagnosis is more difficult in PVE than in NVE. Clinical presentation
is frequently atypical, particularly in the early postoperative period,
in which fever and inflammatory syndromes are common in the ab-
sence of IE. However, persistent fever should trigger the suspicion
of PVE. As in NVE, diagnosis of PVE is based mainly on the results of
echocardiography and blood cultures. However, both are more fre-
quently negative in PVE.100 Although TOE is mandatory in suspected
PVE (Figure 3), its diagnostic value is lower than in NVE. A negative
echocardiogram is frequently observed in PVE2 and does not rule
out the diagnosis, but identification of a new periprosthetic leak is
a major criterion, in which case an additional imaging modality could
be considered (such as CT or nuclear imaging).
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In PVE, staphylococcal and fungal infections are more frequent
and streptococcal infection less frequent than in NVE. Staphylo-
cocci, fungi and Gram-negative bacilli are the main causes of early
PVE, while the microbiology of late PVE mirrors that of NVE, with
staphylococci, oral streptococci, S. bovis and enterococci being the
most frequent organisms, more likely due to community-acquired
infections. Staphyloccoci and enteroccoci are the most common
agents in prosthetic valve implantation endocarditis.345,346
The Duke criteria have been shown to be helpful for the diagnosis
of NVE, with a sensitivity of 70–80%,100,347 but are less useful in PVE
because of their lower sensitivity in this setting.348,349 Recently, nuclear
techniques, particularly 18F-FDG PET/CT, have been shown to be use-
ful for the diagnosis of PVE.93 The addition of abnormal FDG uptake as
a novel major criterion for PVE has thus been pointed out. An algo-
rithm for evaluation of patients with suspected PVE, including echocar-
diography and PET/CT has been suggested (see Figure 3).93
12.1.3 Prognosis and treatment
A very high in-hospital mortality rate of 20–40% has been reported
in PVE.338,341 As in NVE, prognostic assessment is of crucial im-
portance in PVE, as it allows identification of high-risk subgroups
of patients in whom an aggressive strategy may be necessary.
Several factors have been associated with poor prognosis in
PVE,161,216,350–353 including older age, diabetes mellitus, healthcare-
associated infections, staphylococcal or fungal infection, early PVE,
HF, stroke and intracardiac abscess. Among these, complicated
PVE and staphylococcal infection are the most powerful markers.
These patients need aggressive management, consisting of antibiotic
therapy and early radical surgery.
Antimicrobial therapy for PVE is similar to that for NVE. An ex-
ception is S. aureus PVE, which requires a more prolonged (≥6
weeks) antibiotic regimen (particularly in association with aminogly-
cosides) and frequent use of rifampin.
Surgery for PVE follows the general principles outlined for NVE.
Radical debridement in these cases means removal of all infected
foreign material, including the original prosthesis, and any calcium
remaining from previous surgery. Homografts, stentless xenografts
or autografts may be considered in aortic PVE, and homograft or
xenograft root replacement is indicated for any abnormality of the
aortic root that distorts the aortic sinuses. Alternatively, a valved
Dacron conduit336 can be used.
The best therapeutic option in PVE is still debated.221,354–359 Al-
though surgery is generally considered the best option when PVE
causes severe prosthetic dysfunction or HF,220 it was performed in
only 50% of patients with PVE in the Euro Heart Survey,54 a similar
rate as for patients with NVE. Other groups have reported similar
data.221,340 Early surgery was associated with lower in-hospital and
1-year mortality in a large cohort of 4166 patients including both na-
tive and prosthetic valve IE complicated by HF.216 Conversely, after
adjustment for differences in clinical characteristics and survival
bias, early valve replacement was not associated with lower mortality
compared with medical therapy in a large international cohort.37
However, in these series, surgery was beneficial in the subgroup of
patients with the greatest need for surgery, including valve regurgita-
tion, vegetation and dehiscence or paravalvular abscess/fistula.37
Therefore a surgical strategy is recommended for PVE in high-risk
subgroups identified by prognostic assessment, i.e. PVE complicated
by HF, severe prosthetic dysfunction, abscess or persistent fever
(Table 22). Emergency surgery is indicated only in cases with refrac-
tory congestive HF leading to pulmonary oedema or shock, as in
NVE. Conversely, patients with uncomplicated non-staphylococcal
and non-fungal late PVE can be managed conservatively.350,357,358
However, patients who are initially treated medically require close
follow-up because of the risk of late events.
In summary, PVE represents 20% of all cases of IE, with an increas-
ing incidence. The diagnosis of PVE is more difficult than for NVE.
Complicated PVE and staphylococcal PVE are associated with a
worse prognosis if treated without surgery. These forms of PVE
must bemanaged aggressively. Patients with uncomplicated, non-
staphylococcal late PVE can be managed conservatively with
close follow-up.
12.2 Infective endocarditis affecting
cardiac implantable electronic devices
12.2.1 Introduction
Infection of cardiac implantable electronic devices (CIEDs) is a severe
disease associated with high mortality.360 The increased rates of CIED
implantation coupled with increased implantation in older patients
with more co-morbidities have set the stage for higher rates of
CIED infection and the increasing frequency of IE in these patients.361
The reported incidence of permanent pacemaker infection varies
widely among studies.362,363 A population-based study found an inci-
dence of CIED infection of 1.9 per 1000 device-years and a higher
probability of infection after implantable cardioverter defibrillators
compared with permanent pacemakers.364 Both diagnosis and thera-
peutic strategy are particularly difficult in these patients.365
12.2.2 Definitions of cardiac device infections
A distinction should be made between local device infection and
cardiac device-related IE (CDRIE). Local device infection is defined
as an infection limited to the pocket of the cardiac device and is clin-
ically suspected in the presence of local signs of inflammation at the
generator pocket, including erythema, warmth, fluctuance, wound
dehiscence, erosion, tenderness or purulent drainage.366 CDRIE is
defined as an infection extending to the electrode leads, cardiac
valve leaflets or endocardial surface. However, differentiating local
device infection and CDRIE is frequently difficult. In one study,367
culture of intravascular lead segments was positive in 72% of 50 pa-
tients with manifestations strictly limited to the implantation site.
However, the possibility of intraoperative contamination of the
lead tip cannot be excluded in these patients.
12.2.3 Pathophysiology
The pocket may become infected at the time of implantation, during
subsequent surgical manipulation of the pocket or if the generator
or subcutaneous electrodes erode through the skin. Pocket infec-
tion may track along the intravascular portion of the electrode to
involve the intracardiac portion of the pacemaker or implantable
cardioverter defibrillator. Alternatively, the pocket or intracardiac
portion of the electrode may become infected as a result of haema-
togenous seeding during a bacteraemia secondary to a distant in-
fected focus. The consequence may be formation of vegetations,
which can be found anywhere from the insertion vein to the super-
ior vena cava, on the lead or on the tricuspid valve, as well as on the
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right atrial and ventricular endocardium. Septic pulmonary embol-
ism is a very frequent complication of CDRIE.
12.2.4 Risk factors
Several factors have been associated with CIED infections.366,367 Patient
factors include renal failure, corticosteroid use, congestive HF, haema-
toma formation, diabetes mellitus and anticoagulation use.368–370 In
addition, procedural characteristics may also play an important role in
the development of CIED infection. The factors associated with
an increased risk of infection include the type of intervention,371,372
device revisions, the site of intervention, the amount of indwelling
hardware, the use of pre-procedural temporary pacing, failure to ad-
minister perioperative antimicrobial prophylaxis,373 fever within the
24 h before implantation and operator experience.374
12.2.5 Microbiology
Staphylococci, and especially CoNS, account for 60–80% of cases in
most reported series.375,376 A variety of CoNS species have been
described.366,377 Methicillin resistance among staphylococci varies
among studies,376,378 but a low frequency of methicillin-resistant
CoNS has been reported among individuals with no healthcare
contact, whereas a high rate of methicillin resistance in CoNS
is associated with a healthcare environment source.379 Polymicro-
bial infection sometimes involves more than one species of
CoNS.376,380,381 Corynebacterium spp., Propionibacterium acnes,
Gram-negative bacilli and Candida spp. are rarely identified as patho-
gens in CIED infection.366,376,377
12.2.6 Diagnosis
Clinical presentation is frequently misleading, with predominant re-
spiratory and rheumatological symptoms as well as local signs of in-
fection.382 CDRIE must be suspected in the presence of unexplained
fever in a patient with a CIED. Fever is frequently blunted, particu-
larly in elderly patients. As in other forms of IE, echocardiography
and blood cultures are the cornerstones of diagnosis. S. aureus bac-
teraemia might be the sole manifestation of device infection.
Echocardiography plays a key role in CDRIE and is helpful for the
diagnosis of both lead vegetations and tricuspid involvement, quanti-
fication of tricuspid regurgitation, sizing of vegetations and follow-up
after lead extraction. Several prognostic features may be better de-
fined on TTE than on TOE, such as pericardial effusion, ventricular
dysfunction and pulmonary vascular pressure estimations. TOE has
superior sensitivity and specificity to TTE for diagnosis of lead-related
endocarditis.381–385 TOE allows visualization of the lead in atypical lo-
cations, such as the proximal superior vena cava, and of regions that
are difficult to visualize by TTE. In addition, the sensitivity of TOE for
left-sided involvement and for perivalvular extension of infection is
superior to that of TTE. Considering their complementary role, it is
recommended to perform both investigations in suspected CDRIE.
In the presence of infective material along the lead course not
providing typical vegetations of measurable size, both TTE and
TOE may be falsely negative in CDRIE. Intracardiac echocardiog-
raphy was recently found to be feasible and effective in cardiac de-
vice patients386 and to have a superior sensitivity for the detection
of vegetations in cardiac devices.386 – 388
A normal echographic examination does not rule out CDRIE. In
difficult cases, other modalities such as radiolabelled leucocyte
scintigraphy389 and 18F-FDG PET/CT scanning108,390 have been de-
scribed as additive tools in the diagnosis of CDRIE and related com-
plications, including pulmonary septic embolism.
The Duke criteria are difficult to apply in these patients because
of lower sensitivity.347 Modifications of the Duke criteria have been
proposed,382,391 including local signs of infection and pulmonary
embolism as major criteria.382
12.2.7 Treatment
CDRIE must be treated by prolonged antibiotic therapy associated
with complete hardware removal.360,391
12.2.8 Antimicrobial therapy
Antimicrobial therapy for CDRIE should be individualized and based
on culture and susceptibility results if possible (see section 7). Be-
cause most CDRIE infections are secondary to staphylococcal species
and, of those, up to 50% are methicillin-resistant,376,392 vancomycin
should be administered initially as empirical antibiotic coverage until
microbiological results are known. Daptomycin, approved for right-
side IE and bacteraemia attributable to S. aureus,168 is a promising mol-
ecule to treat CIED infection.393–395 Before hardware removal, but
after blood cultures, i.v. antibiotics should be initiated. There are no
clinical trial data to define the optimal duration of antimicrobial ther-
apy. The duration of therapy should be 4–6 weeks in most cases.362
At least 2 weeks of parenteral therapy is recommended after extrac-
tion of an infected device for patients with bloodstream infection.
Patients with sustained (.24 h) positive blood cultures despite
CIED removal and appropriate antimicrobial therapy should receive
parenteral therapy for at least 4 weeks.362,366
12.2.9 Complete hardware removal (device and lead
extraction)
In the case of definite CDRIE, medical therapy alone has been asso-
ciated with high mortality and risk of recurrence.360,363,391 For this
reason, CIED removal is recommended in all cases of proven CDRIE
and should also be considered when CDRIE is only suspected in the
case of occult infection without any apparent source other than the
device.396
Complete removal of the system is the recommended treatment
for patients with established CDRIE.363,391,396 Considering the in-
herent risk of an open surgical procedure,380 transvenous lead ex-
traction has become the preferred method. It is essential to
remove all hardware to avoid the recurrence of infection.368,397 In
experienced centres, procedural mortality rates have been shown
to be between 0.1% and 0.6%.396,398 Long-term mortality varies
among subgroups, but rates are higher in systemic infections.399
Transvenous extractions are not without risk, and procedural com-
plexity may vary significantly according to lead type and features.
Typically ICD leads are more difficult to remove than coronary sinus
leads, which are usually removed by simple manual traction.400 – 402
Transvenous lead extraction should be performed only in centres
committed to a procedural volume allowing the maintenance of
skills of adequately trained teams and able to provide immediate car-
diothoracic surgery backup in the event of emergency thoracotomy
or sternotomy.396,403
Pulmonary embolism as a result of vegetation displacement dur-
ing extraction occurs frequently, particularly when vegetations are
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large.367,404 However, these episodes are frequently asymptomatic,
and percutaneous extraction remains the recommended method
even in cases of large vegetations,360,391,404 as overall risks are
even higher with surgical extraction.367,380
Some authors recommend surgery in patients with very large ve-
getations.405 Until additional data are available, decisions regarding
percutaneous versus surgical removal of leads with vegetations
.2 cm in diameter should be individualized.
Other indications for a surgical approach to lead removal include
patients who need a contemporary valve replacement or repair for
IE or patients who have significant retained hardware after attempts
at percutaneous removal. However, mortality associated with surgi-
cal removal is high in these frequently elderly patients with asso-
ciated co-morbidities.380
12.2.10 Reimplantation
The first step before reimplantation is a re-evaluation of the indica-
tion for CIED implantation.377,403 In a significant number of cases,
reimplantation is not necessary.366,398 The device should be reim-
planted on the contralateral side. There is no clear recommendation
concerning the optimal timing of reimplantation. Factors such as
persistent bacteraemia, persistent vegetation and pacemaker and
implantable cardioverter defibrillator dependency should be con-
sidered and the decision adapted to the individual patient. Immedi-
ate reimplantation should be avoided, owing to the risk of new
infection.366,377,398,403 Blood cultures should be negative for at least
72 h before placement of a new device. In cases of evidence of
remnant valvular infection, implantation should be delayed for at
least 14 days.366,406
Temporary pacing is a risk factor for subsequent cardiac device
infection367 and should be avoided if possible. In pacing-dependent
patients, temporary use of active fixation leads connected to exter-
nal devices is described as a ‘bridge’,407 permitting earlier mobiliza-
tion with a reduced risk of pacing-related adverse events.408 – 410
12.2.11 Prophylaxis
Although there are no large controlled studies on this topic, anti-
biotic prophylaxis is recommended before implantation.367,368,373
A first-generation cephalosporin, such as cefazolin (6 g/day for
24–36 h after the intervention), is usually used as prophylaxis and
should be parenterally administered 1 h before the procedure.
Vancomycin, teicoplanin and daptomicin may be considered in-
stead of cefazolin in centres where oxacillin resistance among
staphylococci is high, in high-risk patients or in patients with contra-
indications to cephalosporins. They should always be started before
the procedure according to the drug pharmacokinetics.
In summary, CDRIE is one of the most difficult forms of IE to diag-
nose andmust be suspected in the presence of frequentlymislead-
ing symptoms, particularly in elderly patients. Prognosis is poor,
probably because of its frequent occurrence in elderly patients
with associated co-morbidities. In themajority of patients, CDRIE
must be treated by prolonged antibiotic therapy and device re-
moval. Table 25 summarizes the main features concerning diag-
nosis, treatment and prevention of CDRIE.
Table 25 Cardiac device-related infective
endocarditis: diagnosis, treatment and prevention
Recommendations Classa Levelb Ref.c
A. Diagnosis
1. Three or more sets of blood
cultures are recommended before
prompt initiation of antimicrobial
therapy for CIED infection
I C
2. Lead-tip culture is indicated when
the CIED is explanted
I C
3. TOE is recommended in patients
with suspected CDRIE with
positive or negative blood
cultures, independent of the
results of TTE, to evaluate
lead-related endocarditis and heart
valve infection
I C
4. Intracardiac echocardiography may
be considered in patients with
suspected CDRIE, positive blood




scintigraphy and 18F-FDG PET/CT
scanning may be considered
additive tools in patients with




B. Principles of treatment
1. Prolonged (i.e. before and after
extraction) antibiotic therapy and
complete hardware (device and
leads) removal are recommended
in definite CDRIE, as well as
in presumably isolated pocket
infection
I C
2. Complete hardware removal
should be considered on the
basis of occult infection
without another apparent source
of infection
IIa C
3. In patients with NVE or PVE
and an intracardiac device with
no evidence of associated
device infection, complete
hardware extraction may be
considered
IIb C
C. Mode of device removal
1. Percutaneous extraction is
recommended in most patients














12.3 Infective endocarditis in the intensive
care unit
Admission to the intensive care unit (ICU) is frequently a part of the
normal patient pathway following surgery for IE. In addition, patients
with IE may be admitted to the ICU due to haemodynamic instability
related to severe sepsis, overt HF and/or severe valvular pathology or
organ failure from IE-related complications.411,412 The incidence of
nosocomial infection is increasing and patients may develop IE as a re-
sult of healthcare-associated infection acquired during hospital or in-
tensive care admission. Finally, the diagnosis of IE can be challenging,
being made only post-mortem in a number of patients.413 Despite ad-
vances in diagnosis and treatment, mortality remains particularly high
in critically ill patients, ranging from 29% to 84%.411,414,415
Estimation of the number of patients requiring ICU admission for
IE is challenging. In a retrospective, multicentre, observational study
of 4106 patients admitted to four medical ICUs, IE was identified in
0.8% of admissions.416 Reasons for admission to the ICU were con-
gestive cardiac failure (64%), septic shock (21%), neurological de-
terioration (15%) and cardiopulmonary resuscitation (9%).416
Critical care morbidity is high, with up to 79% of patients requiring
mechanical ventilation, 73% inotropic support and 39% developing
renal failure.
12.3.1 Organisms
Limited data are available regarding causative organisms for IE in the
ICU. Case series have revealed Staphylococci spp. to be the most
common causative agent, accounting for 74% of all nosocomial IE
cases. Streptococci are the second most common causative organ-
isms. Fungal IE is an increasing problem in the ICU, with Candida IE
occurring significantly more often in ICU than non-ICU hospitalized
patients.417 There should be a high index of suspicion for fungal IE in
the ICU setting, in particular where there is failure to respond to
empirical antimicrobial therapy.
12.3.2 Diagnosis
The diagnostic criteria for IE in the ICU are identical to those for the
non-ICU patient population. However, clinical manifestations may be
atypical and the classic features may be masked by concomitant path-
ology and critical care interventions. Thus pyrexia may be attributed
to co-existing hospital-acquired infections, neurological manifesta-
tions masked by the confounding factors of sedation, ICU-related de-
lirium, concomitant multiple pathologies and acute kidney injury
ascribed to co-existing pathologies. Echocardiography can be chal-
lenging in the intensive care setting, with a reduced sensitivity of
TTE for the diagnosis of IE. There should be a relatively low thresh-
old for TOE in critically ill patients with S. aureus catheter-related
bloodstream infection because of its high propensity to cause IE,
and also, if negative, this may allow short antibiotic treatment.
12.3.3 Management
Patients with severe sepsis or septic shock should be managed ac-
cording to protocolised international guidelines.418 Antimicrobial
management and indications for surgery in patients with IE are de-
scribed in sections 7 and 10, respectively. However, emergency/sal-
vage status accounts for the highest mortality rates in registry data
for patients operated on for IE,299 and patients with SOFA scores
.15 on the day of surgery have extremely poor outcomes.125 De-
cision making in this most critically ill patient population where indi-
cations and contraindications for cardiac surgery co-exist is
challenging and should be undertaken in the context of the multi-
professional, multidisciplinary Endocarditis Team environment.
12.4 Right-sided infective endocarditis
Right-sided IE accounts for 5–10% of IE cases.419,420 Although it may
occur in patients with a pacemaker, ICD, central venous catheter or
CHD, this situation is most frequently observed in IVDAs, especially
in patients with concomitant human immunodeficiency virus (HIV)
seropositivity or in immunosuppressed patients.420 – 422 S. aureus is
the predominant organism (60–90% of cases),419,423 with methicil-
lin-resistant strains becoming more prevalent.414 The frequency of
polymicrobial infections is also rising.424 The tricuspid valve is most
Table 25 Continued
Recommendations Classa Levelb Ref.c
2. Surgical extraction should be
considered if percutaneous
extraction is incomplete or




3. Surgical extraction may be




1. After device extraction,
reassessment of the need for
reimplantation is recommended
I C
2. When indicated, definite
reimplantation should be postponed
if possible, to allow a few days or
weeks of antibiotic therapy
IIa C
3. A ‘temporary’ ipsilateral active
















2. Potential sources of sepsis should be
eliminated ≥2 weeks before
implantation of an intravascular/
cardiac foreign material, except in
urgent procedures
IIa C
CDRIE ¼ cardiac device-related infective endocarditis; CIED ¼ cardiac
implantable electronic device; FDG ¼ fluorodeoxyglucose; IE ¼ infective
endocarditis; NVE ¼ native valve endocarditis; PET ¼ positron emission
tomography; PVE ¼ prosthetic valve endocarditis; TOE ¼ transoesophageal











frequently affected, but other valves—including left-sided—may also
become infected.425 In-hospital mortality is approximately 7%.426–429
12.4.1 Diagnosis and complications
The usual manifestations of right-sided IE are persistent fever, bacter-
aemia and multiple septic pulmonary emboli, which may manifest as
chest pain, cough or haemoptysis. When systemic emboli occur,
paradoxical embolism or associated left-sided IE should be consid-
ered. Isolated right HF is rare, but can be caused by pulmonary hyper-
tension or severe right-sided valvular regurgitation or obstruction.425
Pulmonary hypertension can be secondary to left-sided IE.
TTE usually allows assessment of tricuspid involvement because
of the anterior location of this valve and usual large vegeta-
tions.430,431 Eustachian and pulmonary valves should always be as-
sessed. TOE is more sensitive in the detection of pulmonary
vegetations432 and associated left-sided involvement.
12.4.2 Prognosis and treatment
Vegetation length .20 mm and fungal aetiology were the main pre-
dictors of death in a large retrospective cohort of right-sided IE in
IVDAs.433 In HIV-infected patients, a CD4 count ,200 cells/mL
has a high prognostic value.420,421
12.4.2.1 Antimicrobial therapy
The choice of empiric antimicrobial therapy depends on the sus-
pected microorganism, type of drug and solvent used by the addict
and the infection location.424 In any case, S. aureus must always be
covered. Initial treatment includes penicillinase-resistant penicillins,
vancomycin or daptomycin, depending on the local prevalence of
MRSA,424 in combination with gentamicin. If the patient is a pentazo-
cine addict, an antipseudomonas agent should be added.434 If an
IVDA uses brown heroin dissolved in lemon juice, Candida spp.
(not Candida albicans) should be considered and antifungal treat-
ment added.435 Once the causative organisms have been isolated,
therapy has to be adjusted.
Consistent data show that 2-week treatment may be sufficient
and that the addition of an aminoglycoside may be unnecessary.436
Two-week treatment with oxacillin (or cloxacillin) without gentami-
cin is effective for most patients with isolated tricuspid IE if all the
following criteria are fulfilled:
† MSSA,
† Good response to treatment,
† Absence of metastatic sites of infection or empyema,
† Absence of cardiac and extracardiac complications,
† Absence of associated prosthetic valve or left-sided valve
infection,
† ,20 mm vegetation, and
† Absence of severe immunosuppression (,200 CD4 cells/mL)
with or without acquired immune deficiency syndrome (AIDS).
Because of limited bactericidal activity, poor penetration into vege-
tations and increased drug clearance in IVDAs, glycopeptides
(vancomycin) should not be used in a 2-week treatment. The stand-
ard 4–6-week regimen must be used in the following situations:
† Slow clinical or microbiological response (. 96 h) to antibiotic
therapy;426
† Right-sided IE complicated by right HF, vegetations .20 mm,
acute respiratory failure, septic metastatic foci outside the lungs
(including empyema) or extracardiac complications, e.g. acute re-
nal failure;426
† Therapy with antibiotics other than penicillinase-resistant
penicillins;437
† IVDA with severe immunosuppression (CD4 count ,200 cells/
mL) with or without AIDS;438 or
† Associated left-sided IE.
Alternatively, when conventional i.v. route therapy is not possible,
right-sided S. aureus IE in IVDAs may also be treated with oral cipro-
floxacin [750 mg bis in die (b.i.d.)] plus rifampicin (300 mg b.i.d.) pro-
vided that the strain is fully susceptible to both drugs, the case is
uncomplicated and patient adherence is monitored carefully.439
One randomized controlled study has demonstrated the non-
inferiority of daptomycin compared with standard therapy in the
treatment of S. aureus infections, including right-sided IE.168 When
using daptomycin, most authors recommend using high doses
(10 mg/kg/24 h) and combining it with cloxacillin or fosfomycin to
avoid the development of resistance to this drug.174 Glycopeptides
(e.g. vancomycin) or daptomycin are the agents of choice for MRSA
infections. Vancomycin may have a lower efficacy in infections
caused by MRSA strains with a vancomycin MIC .1 mg/
mL.171,172,440 In these cases, daptomycin would be the drug of
choice. For organisms other than S. aureus, therapy in IVDAs does
not differ from that in non-IVDAs.
12.4.2.2 Surgery
Given the high recurrence rate of IE due to continued drug
abuse, surgery should generally be avoided in IVDAs with right-
Table 26 Indications for surgical treatment of right-sided infective endocarditis
Recommendation Classa Levelb
Surgical treatment should be considered in the following scenarios:
† Microorganisms difficult to eradicate (e.g. persistent fungi) or bacteraemia for. 7 days (e.g. S. aureus, P. aeruginosa) despite adequate
antimicrobial therapy or
† Persistent tricuspid valve vegetations. 20 mm after recurrent pulmonary emboli with or without concomitant right heart failure or
† Right HF secondary to severe tricuspid regurgitation with poor response to diuretic therapy
IIa C










sided native IE, but it has to be considered in the following situations
(Table 26):
† Right HF secondary to severe tricuspid regurgitation with poor
response to diuretic therapy;
† IE caused by organisms that are difficult to eradicate (e.g. persist-
ent fungi) or bacteraemia for at least 7 days (e.g. S. aureus, Pseudo-
monas aeruginosa) despite adequate antimicrobial therapy;441 and
† Tricuspid valve vegetations .20 mm that persist after recurrent
pulmonary emboli with or without concomitant right HF.426,433
Cardiac surgery in HIV-infected IVDAs with IE does not worsen the
prognosis of either the IE or the HIV.
Recent nationwide data have shown that the three most frequent
surgical strategies for tricuspid valve IE are valvectomy, valve repair
and valve replacement.429 Tricuspid valve replacement accounted
for the majority of cases, with most receiving a bioprosthetic valve.
Some authors prefer valve repair (avoiding artificial material when-
ever possible) over valve replacement, but the former did not im-
prove outcomes over valve replacement or valvectomy.429
Valvectomy without prosthetic replacement can be done in ex-
treme cases, but may be associated with severe postoperative right
HF, particularly in patients with pulmonary hypertension. In these
cases, the valve can be subsequently replaced once infection has
been cured and drug use discontinued. Pulmonary valve replace-
ment should be avoided, but if judged necessary, use of a pulmonary
homograft (or, if unavailable, a xenograft valve) is preferred.
In summary, right-sided IE is primarily a disease that affects IVDAs
and patients with CHD. Diagnostic features include respiratory
symptoms and fever. S. aureus is responsible for most cases.
TTE is of major value in these patients. Despite relatively low in-
hospital mortality, right-sided IE has a high risk of recurrence in
IVDAs and surgery is recommended only for intractable symp-
toms, failure of medical therapy, recurrent septic emboli to the
lungs or paradoxical emboli.
12.5 Infective endocarditis in congenital
heart disease
The population of children and adults with CHD is expanding, and
this is the major substrate for IE in younger patients. However, our
knowledge of IE in this setting is limited since systematic studies are
few and often retrospective and selection bias associated with stud-
ies from highly specialized centres hampers universal application.
The reported incidence of IE in CHD is 15–140 times higher than
that in the general population (the highest estimate originating from
a highly specialized unit).442,443 The incidence is lower in children
(0.04% per year) than in adults with CHD (0.1% per year).444,445
The reported proportion of CHD in patients with IE varies (prob-
ably due to selection bias) by between 2% and 60%,446– 450 with a
consistent minor male dominance.443,451,452
Some simple lesions, such as secundum atrial septal defect and
pulmonary valve disease, carry a low risk of IE, while others, such
as bicuspid aortic valve, carry higher risk. However, CHD often con-
sists of multiple cardiac lesions, each contributing to the total risk of
IE. For example, the incidence of IE is considerably higher in patients
with a ventricular septal defect when there is associated aortic
regurgitation.453
The distribution of causative organisms does not differ from the
pattern found in acquired heart disease, with streptococci and
staphylococci being the most common strains.443,451,452
As in other groups, the diagnosis of IE is often made too late, high-
lighting the need to consider the diagnosis of IE in any patient with
CHD presenting with ongoing fever or other signs of ongoing infec-
tion. Blood cultures should be taken before starting antibiotic treat-
ment. The principal symptoms, complications and basis for diagnosis
do not differ from IE in general. However, right-sided IE is more fre-
quent in CHD than in acquired cardiac disease. The superiority of
TOE over TTE has not been systematically studied in this setting.
Nevertheless, complex anatomy and the presence of artificial mater-
ial may reduce the rate of detection of vegetations and other features
of IE, thus favouring the addition of TOE, particularly in the adult
group.443 However, a negative study does not exclude the diagnosis.
Care of CHD patients with IE, from diagnosis to treatment, is best
provided by specialized CHD centres with expertise in imaging, sur-
gery and intensive care. Cardiac surgery is appropriate when med-
ical therapy fails, when serious haemodynamic complications arise
and when there is a high risk of devastating septic embolism.
IE in CHD carries a mortality rate of 4–10%.443,451,452,454 This bet-
ter prognosis compared with acquired heart disease may reflect the
higher proportion of right-heart IE or the better care in CHD centres.
Primary prevention is vital.455 The importance of good oral,
dental and skin hygiene has already been emphasized, and antibiotic
prophylaxis is indicated in high-risk groups as defined in
section 3. However, there is also an educational problem, especially
in patients not followed in specialist CHD centres, and awareness of
the risk of IE and the need for preventive measures are not satisfac-
torily highlighted in the population with CHD.456 Cosmetic tattoo-
ing and piercing, at least involving the tongue and mucous
membranes, should be discouraged in this group.
Surgical repair of CHD often reduces the risk of IE, provided
there is no residual lesion.447,457 However, in other cases when arti-
ficial valve substitutes are implanted, the procedure may increase
the overall risk of IE. There are no scientific data justifying cardiac
surgery or percutaneous interventions (e.g. closure of a patent duc-
tus arteriosus) with the sole purpose of eliminating the risk of IE.458
Cardiac repair as a secondary preventive measure to reduce the risk
of recurrent IE has been described but not systematically studied.
In summary, IE in CHD is rare and more frequently affects the right
heart. Care of CHD patients with IE, from diagnosis to treatment, is
best provided by specialist CHD centres with expertise in imaging,
surgery and intensive care. This applies to most patients with CHD.
Complex anatomy makes echocardiographic assessment difficult.
However, the diagnosis should be considered in all CHD patients
with ongoing infection or fever. Prognosis is better than in other forms
of IE, with amortality rate of <10%. Preventivemeasures and patient
education are of particular importance in this population.
12.6 Infective endocarditis during
pregnancy
A challenge for the physician during pregnancy in the cardiac patient is
the changing cardiovascular physiology, which can mimic cardiac dis-
ease and confuse the clinical picture.459,460 The incidence of IE during
pregnancy has been reported to be 0.006%.196 The incidence of IE in
patients with cardiac disease is 0–1.2% and is higher in women with a
mechanical prosthetic valve.461–464 Therefore IE in pregnancy is ex-
tremely rare and is either a complication of a pre-existing cardiac lesion
or the result of i.v. drug abuse. Maternal mortality approaches 33%,
with most deaths relating to HF or an embolic event, while foetal
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mortality is reported to be about 29%.196 Close attention should be
paid to any pregnant woman with unexplained fever and a cardiac
murmur.
Rapid detection of IE and appropriate treatment is important in redu-
cing the risk of both maternal and foetal mortality.196 Despite the high
foetal mortality, urgent surgery should be performed during pregnancy
in women who present with HF due to acute regurgitation.
12.7 Antithrombotic therapy in infective
endocarditis
Indications for anticoagulant and antiplatelet therapy are the same in
IE patients as in other patients, and evidence does not support the
initiation of medications interfering with the coagulation system as
adjunctive therapy for IE.258 Thrombolytic therapy is generally con-
traindicated and has sometimes resulted in severe intracranial haem-
orrhage,465 but thrombectomy could be an alternative in selected
patients with ischaemic stroke related to IE (see section 9.1).
The risk of intracranial haemorrhage may be increased in patients
already on oral anticoagulants when IE is diagnosed, especially in pa-
tients with S. aureus PVE.113,466 On the other hand, ongoing oral
anticoagulants during IE development may diminish early embolic
tendencies.467
The recommendations for management of anticoagulant therapy in
IE patients are based on a low level of evidence, and decisions should
be made on an individual basis by the Endocarditis Team. The role of
bridging therapy with unfractionated or low molecular weight heparin
has not been studied in patients with IE, but may have reasonable ad-
vantages in special situations (i.e. in unstable patients) before surgical
decisions are made or to avoid drug interactions.
Evidence does not support initiation of antiplatelet therapy in pa-
tients diagnosed with IE,258 despite promising results in experimen-
tal studies.468 Some cohort studies indicate a possible reduction in
the rate of embolic complications257 or IE development in sub-
groups of patients already on antiplatelet therapy,469 but the data
are contradictory.470,471
12.8 Non-bacterial thrombotic
endocarditis and endocarditis associated
with cancers
12.8.1 Non-bacterial thrombotic endocarditis
Non-bacterial thrombotic endocarditis (NBTE) (i.e. marantic endo-
carditis, Libman–Sacks endocarditis or verrucous endocarditis) is
characterized by the presence of sterile vegetations consisting of fi-
brin and platelet aggregates on cardiac valves. These vegetations are
associated with neither bacteraemia nor with destructive changes of
the underlying valve.472 It is also quite relevant to differentiate true
NBTE versus patients with negative blood cultures due to previous
antibiotic therapy.473
NBTE is a condition associated with numerous diseases such as
cancer, connective tissue disorders (i.e. systemic lupus erythemato-
sus patients possessing antiphospholipid antibodies, called Libman–
Sacks endocarditis), autoimmune disorders, hypercoagulable states,
septicaemia, severe burns or chronic diseases such as tuberculosis,
uraemia or AIDS. It is a potentially life-threatening source of
thromboembolism, its main clinical manifestation.
It is essential to differentiate NBTE from IE. The same initial diag-
nostic workup used for IE is recommended. The diagnosis of NBTE
is difficult and relies on strong clinical suspicion in the context of a
disease process known to be associated with NBTE, the presence of
a heart murmur, the presence of vegetations not responding to anti-
biotic treatment and evidence of multiple systemic emboli.474
The presence of a new murmur or a change in a pre-existing mur-
mur, although infrequent, in the setting of a predisposing disease
should alert the clinician to consider NBTE.
Valvular vegetations in NBTE are usually small, broad based and
irregularly shaped. They have little inflammatory reaction at the site
of attachment, which make them more friable and detachable. Fol-
lowing embolization, small remnants on affected valves (≤3 mm)
may result in false-negative echocardiography results. TOE should
be ordered when there is a high suspicion of NTBE. Left-sided (mi-
tral more than aortic) and bilateral vegetations are more consistent
with NTBE than with IE.475 When an early TOE examination is per-
formed, the prognosis of NTBE is improved.476
Comprehensive haematological and coagulation studies should be
performed to search for a potential cause. Multiple blood cultures
should be undertaken to rule out IE, although negative blood cultures
Table 27 Recommendations for the use of
antithrombotic therapy
Recommendations Classa Levelb Ref.c
Interruption of antiplatelet therapy is
recommended in the presence of major
bleeding
I B 257
In intracranial haemorrhage, interruption
of all anticoagulation is recommended
I C
In ischaemic stroke without haemorrhage,
replacement of oral anticoagulant
(anti-vitamin K) therapy by unfractionated
or low molecular weight heparin for 1–2
weeks should be considered under close
monitoringd
IIa C
In patients with intracranial haemorrhage
and a mechanical valve, unfractionated or
low molecular weight heparin should be
reinitiated as soon as possible following
multidisciplinary discussion
IIa C
In the absence of stroke, replacement of
oral anticoagulant therapy by
unfractionated or low molecular weight
heparin for 1–2 weeks should be
considered in the case of Staphylococcus
aureus IE under close monitoring
IIa C
Thrombolytic therapy is not
recommended in patients with IE
III C




dThere is very limited experience with new oral anticoagulant treatment in the
field of IE.
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can be observed in IE (i.e. previous antibiotic therapy, HACEK group,
fungi, etc.). Immunological assays for antiphospholipid syndrome (i.e.
lupus anticoagulant, anticardiolipin antibodies, and anti-b2-
glycoprotein 1 antibodies; at least one must be positive for the diag-
nosis of antiphospholipid syndrome on at least two occasions 12
weeks apart) should be undertaken in patients presenting with recur-
rent systemic emboli or known systemic lupus erythematous.477
NTBE is first managed by treating the underlying pathology.
If there is no contraindication, these patients should be anti-
coagulated with unfractioned or low molecular weight heparin or
warfarin, although there is little evidence to support this strategy.
In NTBE, the use of direct thrombin or factor Xa inhibitors has
not been evaluated. In antiphospholipid syndrome, lifelong anticoa-
gulation is indicated. A trial comparing rivaroxaban (a factor Xa in-
hibitor) and warfarin in patients with thrombotic antiphospholipid
syndrome is currently in progress.478 However, anticoagulation is
associated with a risk of haemorrhagic conversion of embolic
events. CT of the brain should be performed in patients with
NBTE and cerebral attack before anticoagulation to rule out intra-
cranial haemorrhage.
Surgical intervention, valve debridement and/or reconstruction
are often not recommended unless the patient presents with recur-
rent thromboembolism despite well-controlled anticoagulation.
Other indications for valve surgery are the same as for IE. In the
context of cancer, a multidisciplinary approach is recommended
(Endocarditis Team).
12.8.2 Infective endocarditis associated with cancer
IE may be a potential marker of occult cancers. In a large, Danish,
nationwide, population-based cohort study, 997 cancers were iden-
tified among 8445 IE patients with a median follow-up of 3.5 years.
The risk of abdominal and haematological cancers was high soon
after IE diagnosis (within the first 3 months) and remained higher
than expected in the long-term follow-up (.12 months) for ab-
dominal cancer.479
Several bacteria have been reported in association with colonic
cancer, with the strongest and best-documented relationship with
S. bovis infection, specifically the S. gallolyticus subspecies; S. bovis in-
fection has been related to the presence of gastrointestinal neopla-
sia, which in most cases is colonic adenoma or carcinoma.480
However, it is still a source of debate whether the association of
S. bovis/S. gallolyticus IE with colorectal tumours is merely a conse-
quence of the gastrointestinal lesion or could trigger or promote
colorectal cancer.481
In the setting of S. bovis IE, there is a need for proper microbiologic-
al classification. In case of S. bovis/S. gallolyticus IE, it is recommended to
rule out occult colon cancer during hospitalization. In the absence of
any tumour, scheduling an annual colonoscopy is highly suggested.482
As for other tests (i.e. faecal occult blood), the serology-based
detection of colorectal cancer—serum IgG concentrations against
S. bovis antigens—is neither sensitive (not all colorectal tumours
are colonized by S. bovis) nor specific.483
FDG PET/CT is increasingly used in the diagnostic workup of IE. It
may play an interesting role in detecting gastrointestinal pathological
activity and guide colonoscopy. However, negative PET/CT does
not rule out significant colonic pathology. No study has examined
its clinical value for the detection of occult colorectal cancer in pa-
tients with S. bovis/S. gallolyticus IE.




Antibiotic prophylaxis should be considered for
patients at highest risk for IE:
a. Patients with any prosthetic valve, including
transcatheter valve, or those in whom any
prosthetic material was used for cardiac
valve repair
b. Patients with a previous episode of IE
c. Patients with congenital heart disease
(i.e. any type of cyanotic congenital heart
disease or any type of congenital heart
disease repaired with a prosthetic material)
IIa C
Antibiotic prophylaxis is not recommended in
other forms of valvular or congenital heart disease
III C
Dental procedures
Antibiotic prophylaxis should only be considered
for dental procedures requiring manipulation of
the gingival or periapical region of the teeth or
perforation of the oral mucosa
IIa C
Antibiotic prophylaxis is not recommended for
local anaesthetic injections in non-infected tissues,
treatment of superficial caries, removal of sutures,
dental X-rays, placement or adjustment of
removable prosthodontic or orthodontic
appliances or braces, or following the shedding of




Antibiotic prophylaxis is not recommended for
respiratory tract procedures, including
bronchoscopy or laryngoscopy, transnasal or
endotracheal intubation, gastroscopy,
colonoscopy, cystoscopy, vaginal or caesarean
delivery, TOE or skin and soft tissue procedures
III C
2. Recommendations for referring patients to the
Reference Centre
Patients with complicated IE should be evaluated
and managed at an early stage in a reference
centre with immediate surgical facilities and the
presence of a multidisciplinary Endocarditis Team,
including an ID specialist, a microbiologist, a
cardiologist, imaging specialists, a cardiac surgeon
and, if needed, a specialist in CHD
IIa B
For patients with non-complicated IE managed in
a non-reference centre, there should be early and
regular communication with the reference centre




TTE is recommended as the first-line imaging
modality in suspected IE
I B
TOE is recommended in all patients with clinical
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Recommendations Classa Levelb
TOE is recommended in patients with clinical
suspicion of IE when a prosthetic heart valve or an
intracardiac device is present
I B
Repeat TTE and/or TOE within 5–7 days is
recommended in case of initially negative
examination when clinical suspicion of IE remains
high
I C
Repeat TTE and/or TOE are recommended as
soon as a new complication of IE is suspected




recommended in all cases of IE requiring surgery
I B
4. Treatment
Aortic or mitral NVE or PVE with severe
regurgitation or obstruction causing symptoms of
HF or echocardiographic signs of poor
haemodynamic tolerance must by treated by
urgent surgery
I B
Locally uncontrolled infection (abscess, false
aneurysm, fistula, enlarging vegetation) must by
treated by urgent surgery
I B
Infection caused by fungi or multiresistant
organisms must by treated by urgent surgery
I C
Aortic or mitral NVE or PVE with persistent
vegetations .10 mm after ≥1 embolic episodes
despite appropriate antibiotic therapy must by
treated by urgent surgery
I B
5. Neurological complications
After a silent embolism or transient ischaemic
attack, cardiac surgery, if indicated, is
recommended without delay
I B
Neurosurgery or endovascular therapy are
indicated for very large, enlarging or ruptured
intracranial infectious aneurysms
I C
Following intracranial haemorrhage, surgery
should generally be postponed for ≥1 month IIa B
6. Cardiac device-related infective endocarditis
Prolonged (i.e. before and after extraction)
antibiotic therapy and complete hardware (device
and leads) removal are recommended in definite
CDRIE, as well as in presumably isolated pocket
infection
I C
Percutaneous extraction is recommended in most
patients with CDRIE, even those with vegetations
.10 mm
I B
After device extraction, reassessment of the need
for reimplantation is recommended
I C
Temporary pacing is not routinely recommended III C




7. Recommendations for the use of antithrombotic
therapy
Interruption of antiplatelet therapy is
recommended in the presence of major bleeding
I B
In intracranial haemorrhage, interruption of all
anticoagulation is recommended
I C










of Cardiology, Enrico Cecchi; Kyrgyzstan: Kyrgyz Society of Car-
diology, Alina Kerimkulova; Latvia: Latvian Society of Cardiology,
Ginta Kamzola; Lithuania: Lithuanian Society of Cardiology, Regina
Jonkaitiene; Luxembourg: Luxembourg Society of Cardiology,
Kerstin Wagner; Malta: Maltese Cardiac Society, Daniela Cassar De-
marco; Morocco: Moroccan Society of Cardiology, Jamila Zarzur;
Norway: Norwegian Society of Cardiology, Svend Aakhus; Poland:
Polish Cardiac Society, Janina Stepinska; Portugal: Portuguese
Society of Cardiology, Cristina Gavina; Romania: Romanian Society
of Cardiology, Dragos Vinereanu; Russia: Russian Society of
Cardiology, Filipp Paleev; Serbia: Cardiology Society of Serbia, Bilja-
na Obrenovic-Kircanski; Slovakia: Slovak Society of Cardiology, Va-
sil Hrica´k; Spain: Spanish Society of Cardiology, Alberto San Roman,
Sweden: Swedish Society of Cardiology, Ulf Thile´n; Switzerland:
Swiss Society of Cardiology, Beat Kaufmann; The Netherlands:
Netherlands Society of Cardiology, Berto J. Bouma; Tunisia: Tunis-
ian Society of Cardiology and Cardio-Vascular Surgery, Hedi Baccar;
Turkey: Turkish Society of Cardiology, Necla Ozer; United King-
dom: British Cardiovascular Society, Chris P. Gale; Ukraine: Ukrain-
ian Association of Cardiology, Elena Nesukay.
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